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The pancreas is a gland with both exocrine and endocrine roles. It is both involved 
in digesting food and secreting the hormones that regulate blood glucose. Two important 
diseases related to these two components of the pancreas are pancreatic cancer and 
diabetes.  
The fundamental problem for diabetes is the deficiency of insulin-secreting β cells. 
One strategy to reverse the diabetic condition is to supplement patients with more β cells, 
either by transplantation of in vitro derived β cells or by stimulating endogenous progenitor 
cells to differentiate into mature β cells. In Chapter 2, I describe the study I carried out in 
zebrafish to lineage trace a ptf1a-expressing cell population. Insights we obtained from 
studying the endogenous pancreatic developmental mechanism will hopefully benefit us in 
deriving more efficient method to generate β cells in the future. In Chapter 3, I present the 
work on characterizing an Aldefluor positive, Sca-1 positive progenitor population in the 
adult mouse pancreas. The motivation of this study is that this progenitor population may 
represent a cellular source that could be readily exploited to generate new β cells.  
Another important disease of the pancreas is pancreatic cancer. Rigorous lineage 
tracing studies have shown that acinar cells are the cellular origins for pancreatic ductal 
adenocarcinoma, the predominant type of pancreatic cancer. In Chapter 4, I depict the work 
on the role of Dicer, the master regulator of miRNA pathway, in the pancreatic acinar tissue 




efforts in characterization the role of one particular miRNA cluster, mir-216b-217, during 
the processes of pancreatic acinar cell-fate maintenance and pathophysiological changes of 
pancreatic cancer.  
Together, my thesis work provides new insight into the plasticity of pancreatic cells 
and provide the scientific field with novel tools for further investigating the mechanisms 
of pancreatic development, diabetes and pancreatic cancer. It is hoped my efforts will also 
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Chapter 1 Introduction 
1.1 The cellular composition of the pancreas 
The pancreas is a remarkable organ. It performs both endocrine and exocrine 
functions (Fig. 1.1). The exocrine component consists of two cell types: (1) acinar cells 
that secrete digestive enzymes, including proteases, amylases, lipases and nucleases; and 
(2) ductal cells that convey the enzymes to the intestine. The endocrine component consists 
of five cell types: the glucagon-secreting α cells, the insulin-secreting β cells, the 
somatostatin-secreting δ cells, the ghrelin-secreting ε cells, and the pancreatic polypeptide-
secreting PP cells (Granata et al., 2010). Together, the endocrine cells secrete hormones 
into the bloodstream and these hormones regulate nutrient metabolism and glucose 
homeostasis.  
Around 90% of the pancreas is composed of acinar cells. The acinar cells are 
grouped into units called acini. Acinar cells have polarized arrangement within the acini, 
with basally positioned nuclei and apically located granules of digestive enzyme or 
zymogen (Kern, 1993). Centroacinar cells are located at the junction of acini and ducts 
(Pour, 1994). Centroacinar cells connect with terminal intercalated ducts, which 
sequentially merge to intralobular ducts, interlobular ducts, and finally the main pancreatic 
duct. The pancreatic ductal cells secrete bicarbonate-rich fluid to facilitate transportation 
of the digestive enzymes secreted by acinar cells (Grapin-Botton, 2005; Reichert and 
Rustgi, 2011).  
The endocrine cells are mainly grouped into the structure islets of Langerhans 
(Gomori, 1941; Granata et al., 2010). Scattered and isolated endocrine cells can also be 
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detected within the exocrine parenchyma. These endocrine cells are often associated with 
ducts (Bertelli and Bendayan, 2005; Bertelli et al., 2001).  
 
Figure 1.1: The cellular composition of the pancreas  
(Reproduced from Yale University.) 
Left, artistic rendition of the pancreas. Right, H&E showing a section of adult mouse 
pancreas. 
 
1.2 Pancreas Development  
In the mouse, pancreas development is first noticeable at around embryonic day 
8.5~9.5 (E8.5~E9.5) as the thickenings of multilayered stratified epithelium in the foregut 
endoderm (Fig. 1.2A). The classical model of pancreas tubulogenesis involves epithelial 
budding and branching morphogenesis (Gittes, 2009; Slack, 1995). Recent studies, 
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however, have shown that epithelial polarization and intraepithelial lumen formation are 
required for the establishment of the ductal network in the mouse pancreas (Kesavan et al., 
2009; Villasenor et al., 2010). Specifically, at E11.5, multiple microlumens are formed. 
Starting at E12.5, these lumens coalescence and rearrange into an interconnected tubular 
structure (Kesavan et al., 2009) (Fig. 1.2B). During the first wave of development, there is 
little cellular differentiation except the early appearance of glucagon positive cells (Herrera 
et al., 1991; Rall et al., 1973). Starting at E13.5, dramatic morphogenetic changes, the so-
called “secondary transition”, occur in the pancreas. The process is characterized by rapid 
proliferation and differentiation (Kemp et al., 1972; Pictet et al., 1972). Mature acinar cells 
are specified in the tips of the pancreatic bud, whereas endocrine cells and ductal cells are 
present in the trunk epithelial region (Fig. 1.2C) (Klinck et al., 2011; Kopp et al., 2011b; 









Figure 1.2: Pancreas development. 
Pancreata from Pdx1-GFP transgenic mice at different developmental time points were 
harvested and sectioned. Pdx1 is one of the earliest transcription factors to be expressed 
in the pancreatic field. It marks pancreatic epithelial components during development and 
is restricted to endocrine β cells and δ cells as well as ductal cells in the adult. In all the 
panels, signals from Pdx1-GFP transgene are shown in green. (A) E10.5. The dorsal buds 
are starting to develop. Notice that Pdx1 also expresses in the intestine. DBA (red) labels 
ductal cells (Reichert et al., 2013). DAPI, blue. (B) E12.5. In the dorsal buds, there is early 
onset of tubular morphogenesis. Ecad, red. DAPI, blue. (C) E16.5. The tip and truck 
domains are already evident. Differentiated acinar cells, marked by amylase (red) 
staining, accumulate in the tips. Endocrine populations, including insulin-secreting β cells 
(c-pep, white), are concentrated in the trunk domains. The endocrine population 
maintains high expression of Pdx1. DAPI, blue. (D) P0. Pancreatic morphology starts to 
resemble that of the adult, except that the acinar units are still small and relatively loosely 
attached. Ecad, white. DAPI, blue. (E) 1 month. Further organization of the pancreas. 
Ecad, white. DAPI, blue. (F) In the adult pancreas, fluorescent signals from the Pdx1-GFP 
















A number of critical gene regulatory networds have been identified in the 
developing mouse pancreas. Pancreas transcription factor 1a (Ptf1a) is among the first 
genes to be expressed in the pancreas. Lineage tracing studies in the mouse show that Ptf1a 
is a marker of multipotent progenitor cells in the developing pancreas (Kawaguchi et al., 
2002; Pan et al., 2013). Before E18.5, Ptf1a-expressing cells give rise to all pancreatic 
epithelial lineages including acinar, endocrine and ductal cells (Pan et al., 2013). Ptf1a is 
both necessary and sufficient for early pancreatic organogenesis. In Ptf1a null mice, the 
growth of dorsal and ventral pancreatic buds is severely retarded; there is complete lack of 
acinar cells and the endocrine cell numbers and distribution are altered (Burlison et al., 
2008; Krapp et al., 1998). In addition, in the Ptf1a-deficient state, progenitor cells that 
should have been directed to the pancreatic fate are relocated to the duodenum or common 
bile duct instead (Burlison et al., 2008; Kawaguchi et al., 2002). One further piece of 
evidence, which establishes Ptf1a as the master regulator of pancreatic differentiation, is 
that ectopic expression of Ptf1a, together with another important transcription factor 
pancreatic duodenum homeobox 1 (Pdx1), is capable of converting duodenum to pancreas 
in Xenopus embryos (Afelik et al., 2006).  
In the mature pancreas, the expression of Ptf1a is restricted to the acinar cells, and 
this is important for the maintaining of the pancreatic acinar cell fate. Antagonism of Ptf1a 




Ptf1a is the α-subunit of the trimeric protein complex PTF1. The other two 
components of the complex are the ubiquitous bHLH protein E2A and the Suppressor of 
Hairless (RBP-J) protein or its paralog RBP-JL (Beres et al., 2006). During the early stages 
of pancreatic development, Ptf1a interacts with RBP-J. This interaction is essential for the 
developmental functions of Ptf1a (Masui et al., 2007), one of which is to repress the 
alternative lineage program specified by high expression of Nkx6.1 (Schaffer et al., 2010). 
In mature acinar cells, however, Ptf1a switches its partner from RBP-J to RBP-JL, and 
together, they bind to promoters of acinar-specific genes such as those encoding digestive 
enzymes (Beres et al., 2006; Masui et al., 2010).  
ChIP-seq results demonstrate that the PTF1 complex recognizes a DNA-binding 
sequence containing an E-box (CACCTG) and a TC-box (TTTCCCACG) spaced 1 or 2 
helical DNA-turns apart (Fig. 1.3A) (Beres et al., 2006). A highly conserved 2.3 kb 
genomic region, between -15.6 kb and -13.4 kb relative to the transcriptional start site of 
Ptf1a, has been identified as an enhancer.  The 5’ enhancer contains two bipartite E-box 
and TC-box binding sites and has been shown to be bound by the PTF1 complex, thus 
establishing the autoregulatory loop of Ptf1a (Masui et al., 2008).  
In humans, individuals with mutations in PTF1A present clinically with permanent 
neonatal diabetes mellitus and cerebellar agenesis (Al-Shammari et al., 2011; Hoveyda et 
al., 1999; Sellick et al., 2004; Tutak et al., 2009). The mutations in the PTF1A coding 
sequence uncovered to date are summarized in Fig. 1.3B. Recently, another cluster of 
mutations that are associated with pancreatic agenesis were found in the cis-regulatory 
region located 25kb downstream of PTF1A (Weedon et al., 2014) (Fig. 1.3C).  
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 It is clear that zebrafish ptf1a plays an important role in the establishment of acinar 
cell fate, but its role in endocrine specification is still debatable. On the one hand, there is 
evidence that early endocrine lineage is independent of ptf1a. For example, it has been 
shown that ptf1a down-regulation by morpholinos impairs the development of exocrine 
pancreas, but the differentiation and organization of the principal islet is preserved (Lin et 
al., 2004). On the other hand, data has shown that a reduced level of ptf1a is more favorable 
for endocrine differentiation (Dong et al., 2008). One way to address the question of 
whether ptf1a is ever expressed (and thus likely required) in the endocrine progenitors is 
to carry out lineage-tracing experiments. In Chapter 2, I will present the lineage tracing 
results we obtained from the newly generated ptf1a:creERT2 fish line. Furthermore, the 
transparency of zebrafish larvae and their small size render it possible to carry out imaging 
studies on the whole embryos. As a result, I was able to simultaneously examine all the 
tissues that were labeled in the ptf1a lineage. Lineage analysis shows that in the wildtype 
pancreas, there are limited contribution of ptf1a lineage to pancreatic Notch-responsive-
cells (PNCs) and endocrine fate. ptf1a lineage to some degree contributes to β-cell 
regeneration. However, in the ptf1a heterozygous mutant fish, a higher proportion of ptf1a 
lineage-labeled cells can be traced into PNCs and endocrine compartment. Further 
reduction of ptf1a dosage converts the ventrally derived pancreatic progenitor cells to gall 
bladder and other nonpancreatic cell fate. I shall discuss the different cellular 
differentiation roles of different threshold of ptf1a and the application in in vitro derivation 







Figure 1.3: PTF1 binding sequences and PTF1A mutations identified in human. 
(A) Sequence logos shows the canonical PTF1 binding sites, with an E-box (CACCTG) and 
a TC-box (TTTCCCACG) spaced 1 or 2 helical DNA-turns apart. Position weight matrix 
is based on published data from Masui, et al (Masui et al., 2010). Figure is adapted from 
Dr. Xiaogang Zhong, personal communication. (B) Summary of mutations that have been 
reported in PTF1a coding sequence. Figure is reprinted from Al-Shammari, et al (Al-
Shammari et al., 2011). (C) Mutations in the upstream enhancer region of PTF1a that are 



















1.4 The sources of new β cells 
The most prevalent disease of the pancreas is diabetes mellitus. There are two major 
types of diabetes. In type 1 diabetes, the body’s immune system attacks its own β cells 
(Gale, 2001). Type 2 diabetes is characterized by peripheral tissue insulin resistance and 
concomitant β-cell noncompensation (Butler et al., 2003). To correct the β-cell deficit of 
diabetes, there are two major areas that are under intense investigation. One is the directed 
differentiation of pluripotent stem cells in vitro and the other is the stimulation of 
regeneration or transdifferentiation of β cells in vivo (Fig. 1.3).  
In vitro strategies that guide the differentiation of pluripotent stem cells into β-cell 
following developmental principles have been developed (D'Amour et al., 2006; Kroon et 
al., 2008). However, before β cells derived in a dish can be used for therapeutic purpose, 
there are major obstacles that have yet to be overcome. For example, the risks of 
tumorigenesis upon transplantation of stem cell-derived tissues have always been of 
concern (Carpenter et al., 2009). Furthermore, these β cells have exhibit a limited respond 
to glucose stimulus while in culture and require a final in vivo maturation step (D'Amour 
et al., 2006; Kroon et al., 2008). Recent studies have shown that these in vitro differentiated 
β cells more closely resemble embryonic β cells than adult mature β cells (Hrvatin et al., 
2014; Xie et al., 2013). 
Endogenously, the potential sources of new β-cells include preexisting β cells, 
acinar cells, α cells, ductal cells, liver cells, intestine cells, and pancreatic progenitor cells. 
A pulse-chase experiment using Ins-creERT2; Z/AP mice was designed to label 
mature β cells with alkaline phosphatase upon tamoxifen injection and chase them over 
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different periods of time. This experiment demonstrated that the percentage of labeled β 
cells is stable in adult life and during β-cell regeneration upon pancreatectomy. No dilution 
of label was observed. This observation implies that self-duplication of pre-existing β cells 
is the source of new β cells (Dor et al., 2004). However, this experiment did not exclude 
the possibility of the existence of progenitor cells, due to the variable labelling efficiency 
of the inducible creERT2 system (Guo et al., 2002; Hebert and McConnell, 2000; 
Kawaguchi et al., 2011).  
Another approach to generate new β-cells is by transdifferentiation. Acinar cells 
are one of the promising sources. The forced expression of three transcription factors, 
Pdx1, MafA and Ngn3 (PMN), is sufficient to convert acinar cells into β cells (Zhou et al., 
2008). Suppression of Ptf1a activity induces acinar-to-endocrine conversion (Hesselson et 
al., 2011). Recently, exciting results presented by Baeyens et al. demonstrate that transient 
administration of epidermal growth factor (EGF) and ciliary neurotrophic factor (CNTF) 
stimulates the conversion of terminally differentiated acinar cells to β-like cells in adult 
mice with chronic hyperglycemia (Baeyens et al., 2014). 
Besides acinar cells, other endocrine cells such as α cells have also been shown to 
be able to reprogram into β cells. Ectopic expression of Pax4 under the glucagon promoter 
was sufficient to convert α cells into β cells (Collombat et al., 2009). Furthermore, under 
conditions of near complete β-cell ablation using the diphtheria toxin system, similar 
reprogramming processes are observed (Thorel et al., 2010). α cells have high levels of 
bivalent epigenetic markers, similar to those seen in embryonic stem cells (ESCs). 
Inhibition of histone methyltransferases leads to partial α-to-β cell-fate conversion 
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(Bramswig et al., 2013). Most recently, it was discovered that in the juvenile mice, there 
were δ-to-β cell conversion under conditions of severe β-cell loss (Chera et al., 2014).  
A fourth cell type residing within the pancreas that has been extensively studied for 
its potential to generate functional β cells is the adult pancreatic ductal cell. Upon 
pancreatic duct ligation, Neurogenin3 (Ngn3), a pancreatic endocrine-determining 
transcription factor expressed during embryonic development, was reported to be activated 
in the duct cells of the ligated pancreas (Xu et al., 2008). However, these Ngn3+ cells did 
not appear to progress further along the endocrine differentiation pathway (Kopp et al., 
2011a; Kopp et al., 2011b; Xiao et al., 2013). 
Apart from pancreatic cell types, other endoderm-derived cells types have been 
reported to sustain the capability of differentiating into β-cell as well. The overexpression 
of Pdx1 or the PMN factors mentioned above in liver induces expression of insulin genes 
(Banga et al., 2012; Ferber et al., 2000). Transient expression of PMN factors similarly 
promotes rapid conversion of intestinal crypt cells into endocrine cells (Chen et al., 2014). 
In addition, ablation of Foxo1 in the intestine generates insulin-producing cells both in 
mouse and human (Bouchi et al., 2014; Talchai et al., 2012). 
One final type of cells that is theoretically capable of differentiating into β cells is 
the pancreatic tissue resident stem /progenitor cells. It has been reported that in the obese 
and pregnant individuals, there are increase in β-cell mass and β-cell number, but this 
increase does not seem to be replication related (Butler et al., 2010; Saisho et al., 2013). 
Furthermore, in the long-duration type 1 diabetic patients, functional β cells are detected 
(Oram et al., 2014). Potentially, there could be neogenesis or progenitor cell differentiation 
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events involved in the expansion of human β cells. Putative adult pancreatic 
stem/progenitor cells that could be clonally expanded and that have multilineage 
differentiation potentials have already been found in mouse pancreas (Choi et al., 2004; 
Inada et al., 2008; Rovira et al., 2010; Seaberg et al., 2004; Smukler et al., 2011; Xu et al., 
2008; Zulewski et al., 2001). In Chapter 3, I will discuss a novel cell type that we identified 
in the mature mouse pancreas that has progenitor cell characteristics. These cells are high 
in Aldefluor activity (A+) and are positive for Sca-1 (Sca-1+). A+Sca-1+ cells are 
upregulated during the regeneration of acute pancreatitis; can differentiate to both 
endocrine and exocrine cell fates in dorsal buds transplantation; secrete signaling 
molecules that are similar to embryonic pancreatic mesenchyme. The unique features of 
these A+Sca-1+ cells make them a potential candidate for the derivation of β cells and they 
may secrete paracrine signals to regulate adult pancreatic homeostasis in both normal and 







Figure 1.4: The sources of new β cells  
(adapted from Pagliuca and Melton (Pagliuca and Melton, 2013).) 
Strategies to generate new β-cells. (A) Directed differentiation in vitro. Different culture 
conditions can drive the differentiation of a pluripotent stem cell (red) through the stages 
of pancreatic differentiation in a manner that mimics normal development. Under current 
protocols, β cells derived in vitro are not functionally mature. A subset of important genes 
expressed at each stage is listed. Differentiation of A+Sca-1+ progenitor cells into β cells 
remain to be achieved. (B) Reprogramming of terminally differentiated cell types, such as 
acinar, α-cells, hepatocytes or enterocyte can be used to generate β cells in vivo.. (C) 
Inducing the replication of existing β-cells is the primary strategy for generating new 
endogenous β cells.  
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1.5 Pancreatic cancer 
Another important disease of the pancreas is pancreatic cancer. Pancreatic cancer 
is currently the fourth leading cause of cancer death in the United States (American-
Cancer-Society, 2014). It is one of the deadliest cancers, with a 5-year survival rate of only 
6% (American-Cancer-Society, 2014). Mutations associated with pancreatic cancer are 
frequently observed in  KRAS, CDKN2A, TP53, BRCA2 and SMAD4/DPC4 (Bardeesy and 
DePinho, 2002). Currently, one of the major efforts to understand the mechanisms of 
pancreatic cancer and provide new therapeutic targets is to identify signature gene 
mutations and functionally annotate them. In so doing, the knowledge accumulated will 
serve as a conceptual framework to guide the future analysis of complex aspects of this 
disease (Biankin et al., 2012). 
Up to 85% of pancreatic cancer cases are pancreatic ductal adenocarcinoma 
(PDAC) (Ghaneh et al., 2002).  PDAC primarily exhibits duct-like structures with varying 
degrees of cellular atypia and differentiation. Pancreatic intraepithelial neoplasia (PanIN) 
is the most common precursor of PDAC (Hruban et al., 2004). PanINs are classified 
morphologically into three grades and each grade has its own characteristic molecular 
signature (Fig. 1.5).  
Lineage tracing experiments in mice suggest that PanINs rarely arise from ducts 
(Brembeck et al., 2003; Kopp et al., 2012), but instead, are most likely derived from acinar 
cells (De La et al., 2008; Guerra et al., 2007; Habbe et al., 2008; Morris et al., 2010). Acinar 
cell dysplastic and metaplastic changes are an important initiation step during the evolution 
of pancreatic cancer (Rooman and Real, 2012).  
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We are interested in studying the biological function of microRNAs (miRNAs). 
miRNAs are small noncoding RNAs of 19-25 nucleotides in length (Ambros, 2004; Bartel, 
2004; Pasquinelli et al., 2005). They are stable and can be quantified in very small amounts 
of material (Zen and Zhang, 2012). Different signatures of miRNAs are associated with 
cancer diagnosis, staging, prognosis and drug response (Calin and Croce, 2006). 
Furthermore, miRNAs have been shown to function as oncogenes or tumor suppressors 
and play an active part in tumor initiation and progression (He et al., 2005; Johnson et al., 
2005; O'Donnell et al., 2005).  
In the pancreas, several miRNA profilings have been carried out to differentiate 
PDAC, pancreatitis and normal pancreas (Bloomston et al., 2007; Liu et al., 2012; Schultz 
et al., 2012; Szafranska et al., 2007; Szafranska et al., 2008; Wang et al., 2009).  The 
expression patterns of miR-217 and mir-196a, for example, discriminate normal pancreas, 
chronic pancreatitis and pancreatic cancer (Szafranska et al., 2007). Moreover, some of the 
miRNAs have been characterized as potent oncogenes or tumor suppressors in their 
corresponding pancreatic cancer models (Hwang et al., 2010; Ji et al., 2009; Ryu et al., 
2010; Yu et al., 2010; Zhao et al., 2010). 
Currently, however, there is no detailed study of the role of miRNAs in normal 
pancreatic tissue differentiation and cell-fate maintenance. To fill in the gap, we created 
knockout mice with deletion of the miRNA pathway master regulator, Dicer, in the adult 
pancreatic acinar cells. Combining conditioned Dicer deletion with the activation of 
oncogenic Kras, we further explored the role of miRNAs during pancreatic cancer initiation 
and progression. Dicer knockout induces morphological changes in the acinar cells, 
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including loss of polarity, epithelial-mesenchymal transition and acinar-ductal metaplasia. 
Dicer dosage is critically regulated during the PanIN initiation. The details will be 
discussed in Chapter 4. In Chapter 5, we consider the function of one particular miRNA 
cluster, mir-216b-217. 
 
Figure 1.5: The progression of pancreatic cancer  
(reprinted from Hruban, et al with permission (Hruban et al., 2000).) 
Progression model for pancreatic cancer. Normal duct epithelium progresses to 
metastatic cancer (left to right) through a series of histologically defined precursors 











Chapter 2 ptf1a lineage tracing in zebrafish. 
2.1 Introduction 
Zebrafish has emerged as a system to study pancreas organogenesis and has 
provided new insights on cellular signaling, lineage hierarchy and other developmental 
mechanisms including β-cell specification during pancreas morphogenesis (Kinkel and 
Prince, 2009; Tiso et al., 2009; Yee et al., 2005). 
Pancreas development in zebrafish shares many features with mammalian pancreas 
development. The mammalian pancreas develops in two stages. During the first wave of 
development, referred to as “primary transition”, there is early formation of an endocrine 
population (Herrera et al., 1991; Rall et al., 1973). In mouse, starting around Embryonic 
Day 13.5 (E13.5), dramatic morphogenetic changes occur. This process is called 
“secondary transition” and is characterized by rapid cellular proliferation and 
differentiation. The mature endocrine population starts to appear at this stage (Kemp et al., 
1972; Pictet et al., 1972). 
Pancreas transcription factor 1a (Ptf1a) is one of the earliest genes expressed in the 
prepanceatic field (Hald et al., 2008). Lineage analysis has shown that mouse Ptf1a marks 
a multilineage progenitor pool that generates both endocrine and exocrine progeny during 
early pancreatic organogenesis. Between E13.5 to E18.5 the lineage contributions of the 
Ptf1a progenitor pool become progressively restricted, and by E18.5, Ptf1a exclusively 
labels cells that are destined to become acinar cells (Kawaguchi et al., 2002; Pan et al., 
2013). In Ptf1a null mice, the growth of pancreas is severely retarded; there is complete 
lack of acinar cells and the endocrine cells become redistributed to spleen (Burlison et al., 
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2008; Krapp et al., 1998). In addition, in the Ptf1a-deficient state, progenitor cells that 
should have been directed to the pancreatic fate instead become incorporated into the 
duodenum or common bile duct (Burlison et al., 2008; Kawaguchi et al., 2002).  
Similar to mammals, the zebrafish pancreas develops from two distinct anlagen 
arising from foregut endoderm, termed the dorsal and ventral pancreatic buds (Field et al., 
2003). While these buds in mammals contain admixed endocrine and exocrine elements, 
there seems to spatial segregation of early zebrafish endocrine and exocrine pancreatic 
lineages. The fish dorsal bud develops first and gives rise to a primary endocrine cluster 
known as the principal islet, while the ventral bud appears later and has traditionally felt to 
be responsible for generating the exocrine ductal and acinar lineages as well as a later 
population of endocrine cells (Field et al., 2003; Hesselson et al., 2009; Lin et al., 2004). 
In zebrafish, the early dorsal bud-derived endocrine population maybe equivalent to the 
endocrine cells originating from primary transition in the mammalian pancreas; while the 
vast majority of mature hormone-producing cells are derived from the secondary transition 
(Hesselson et al., 2009; Parsons et al., 2009). With respect to progenitor cells responsible 
for generating differentiated pancreatic cell types, two populations have been defined in 
zebrafish: a Notch-responsive population and a ptf1a-expressing population (Wang et al., 
2011). Lineage tracing studies have demonstrated that zebrafish Notch-responsive cells 
(PNCs) differentiate to ducts, centroacinar cells and endocrine cells during the secondary 
transition (Parsons et al., 2009; Wang et al., 2011), although it remains unclear whether 
these PNCs may arise from ptf1a-expressing cells. Indeed, the precise contributions of 
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ptf1a-expressing progenitor cells to different pancreatic lineages has not yet been 
determined.  
Previous work has clearly established that zebrafish ptf1a plays an important role 
in the establishment of acinar cell fate, equivalently to the mammalian counterpart (Lin et 
al., 2004). Furthermore, the early endocrine population generated during primary transition 
is independent of ptf1a (Lin et al., 2004; Zecchin et al., 2004). But the role of ptf1a in 
endocrine specification during secondary transition remains unclear. Data has shown that 
a reduced level of ptf1a is more favorable for endocrine differentiation (Dong et al., 2008).  
However, fish lacking ptf1a fail to survive to the point of secondary islet formation, leaving 
open the question of whether these cells are in any way ptf1a-dependent.  To address these 
issues and to trace the fate of zebrafish ptf1a-expressing cells, we generated an inducible 
ptf1a:creERT2 transgenic fish line using BAC recombineering, and employed this line to 
complete formal lineage tracing studies. Early lineage labeling confirmed that ptf1a-
expressing progenitors contribute primarily to the acinar cell lineage.  However, we also 
identified contributions to pancreatic Notch-responsive cells (PNCs) and endocrine cells 
during development. We also demonstrated that ptf1a lineage labeled cells gave rise to new 
β cells during regeneration. Interestingly, heterozygous ptf1asa126/wt mutant fish displayed 
enhanced contributions of ptf1a lineage-labeled cells to the PNC and endocrine cell fates. 
In addition, we observed that, in the absence functional Ptf1a, ptf1a lineage-labeled cells 
were converted into gall bladder and other non-pancreatic cell types. In summary, we 
showed that in the zebrafish pancreas, the early ptf1a-expressing cells displayed limited 
multipotency during development and regeneration. Under conditions where ptf1a dosage 
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was reduced, the multipotency of the ptf1a lineage was enhanced. These findings confirm 
conservation of general mechanisms for pancreas development among vertebrates, while 
highlighting qualitative differences.  
Contributions: Dr. Joon Park created the ptf1a:creERT2 fish line and performed 
initial characterization. Dr. Joon Park contributed Fig. 2.1. All the rest of the work was 
carried out by myself.  
2.2 Materials and Methods 
2.2.1 Generation of transgenic zebrafish lines  
We followed the published BAC recombineering method (Suster et al., 2011) to 
generate the transgene construct tg(ptf1a:creERT2), abbreviated to ptf1a:creERT2, by 
replacing GFP with creERT2 elements in the ptf1a:GFP construct. The ptf1a:GFP construct 
is derived from genomic BAC CH211-142H2 (Park et al., 2008a; Sharan et al., 2009), 
which encompasses the zebrafish ptf1a coding sequence. ptf1a:GFP transgene has been 
shown to accurately recapitulate the endogenous ptf1a expression (Park et al., 2008a; 
Pashos et al., 2013).  
The lineage responder line tg(ubi:loxP-CFP-loxP-nuc-mCherry), abbreviated to 
ubi:loxP-CFP-loxP-nuc-mCherry  was modified from the previously published line 
Tg(T2Kβactin:loxP-stop-loxP-hmgb1-mCherry)jh15 (Wang et al., 2011), where the βactin 
promoter was replaced by the ubiquitin promoter (ubi) (Mosimann et al., 2011). CFP was 
also included in the construct to facilitate the identification of the transgenic fish.  
Ptf1asa126/wt fish were obtained from the Sanger Institute Zebrafish Mutation Project 
(Kettleborough et al., 2013).  
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Stable sst:CFP; ins:dsYFP-2TA-nsfB transgenic fish was established to express 
CFP under somatostatin (sst) promoter, and nsfB encoding Nitroreductase was expressed 
under insulin (ins) promoter  (Pisharath et al., 2007; Walker et al., 2012).   
All fish were maintained under standard conditions. All procedures were performed 
under the approval of the Johns Hopkins University School of Medicine Animal Care and 
Use Committee guidelines. 
2.2.2 Drug treatment 
For the induction of creER activity, 4-Hydroxytamoxifen (4-OHT, T176, Sigma) 
treatment was performed as previously described (Wang et al., 2011). Briefly, 4-OHT was 
dissolved in 100% ethanol to create a stock solution of 10 mM. Embryos were placed in a 
5 μM solution of 4-OHT in E3 medium from 30 to 54 hours post fertilization (hpf), unless 
otherwise stated in the text.  
For the β-cell ablation experiment, Metronidazole (Met, Sigma, M3761) treatment 
was performed as previously described (Pisharath et al., 2007). Briefly, Met was dissolved 
in E3 medium at a concentration of 10mM. Embryos were incubated in the solution for 24 
hours from 82 to 106 hpf. Embryo-containing petri dishes were kept in the dark. 
2.2.3 Immunofluorescence 
For whole mount immunofluorescent staining, larvae were fixed in 4% 
paraformaldehyde at 4°C overnight. Following fixation the whole gut region was dissected 
out and blocked for 1 hour with PBS with 0.2% Triton (PBST) and 10% fetal bovine serum. 
For cryosections, fish were similarly fixed and the gut-intestine system was dissected. 
Tissues were then immersed in 30% sucrose/PBS, embedded in optimal cutting 
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temperature (OCT) compound, frozen in liquid nitrogen, and sectioned in 10 μm thickness 
using a cryostat. Primary antibodies used in this study were: mouse anti-Nkx6.1 
(Developmental Studies Hybridoma Bank, F55A12), 1: 100. Guinea pig anti-Insulin 
(Dako, A0564), 1: 500. Rabbit anti-Glucagon (Dako, A0565), 1:400. Rabbit anti-
Somatostatin (Dako, A0566), 1:500. Rabbit anti-DsRed (Clontech, 642496), 1:100. Mouse 
anti-2F11 (Abcam, ab71286), 1:200. Primary antibodies were incubated at 4°C overnight. 
After washing with PBST, samples were incubated with secondary antibodies (Jackson 
Immunoresearch, 1:300) in blocking buffer. Fluorescent images were acquired with Nikon 
A1 scanning confocal microscope. Cell counting was carried out manually. Briefly, whole 
mount tissues were scanned by confocal microscope and maximum projections were 
assembled from Z-stacks. Cell numbers were counted from reconstructed images. Student 
t-test was implemented for statistical analysis. 
2.3 Results 
2.3.1 Validation of the ptf1a:creERT2 driver line 
To lineage trace ptf1a-expressing cells in a temporarily controlled manner, we 
engineered a large genomic bacterial artificial chromosome (BAC) spanning the ptf1a 
locus. This BAC has been shown to faithfully recapitulate endogenous ptf1a expression 
(Park et al., 2008a) in pancreas, hindbrain, retina and spinal cord.  We replaced ptf1a coding 
sequence with a DNA sequence encoding CreERT2. To facilitate integration of the BAC 
construct into the genome, a cassette containing the inverted left and right arm of the Tol2 
transposable element was used (Suster et al., 2011). Several independent F1 generation 
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ptf1a:creERT2 transgenic lines were established and were crossed onto the ubi:loxp-CFP-
loxp-nuc-mCherry reporter line.  
In order to screen lines for inducible cre activity, ptf1a:creERT2; ubi:loxp-CFP-
loxp-nuc-mCherry double transgenic larvae were treated with 5 µM 4-Hydroxytamoxifen 
(4-OHT) at 1 day post fertilization (dpf) for 24 hours and then fixed for imaging at 5 dpf 
(Fig. 2.1A). These larvae were raised along with untreated controls. At 5 dpf, strong nuc-
mCherry signal was observed in 4-OHT-treated larvae, indicating cre-dependent 
recombination (Fig. 2.1B, d2 and g2). Only rare pancreatic or hindbrain nuc-
mCherry signals were detected in larvae without 4-OHT treatment (Fig. 2.1B, d1 and g1).   
A single transgenic line with the highest fluorescent intensity upon 4-OHT 
treatment and lowest incidence of recombination events without 4-OHT treatment 





Figure: 2.1. Generation of the ptf1a lineage tracing system and its initial 
characterization. 
(Joon Park) 
(A) Schematic of ptf1a:creERT2 driver and responder ubi:loxp-CFP-loxp-nuclear-mCherry. 
Double transgenic fish larvae were treated with 5 µM 4-OHT in E3 medium at 1 dpf for 
24 hours and then fixed for imaging at 5 dpf. These larvae were raised along with 
untreated controls. (B) At 5 dpf, 4-OHT-treated larvae showed nuclear-mCherry signal 
(red) in exocrine pancreas (a2-e2) and hindbrain (f2-h2), indicating ptf1a-dependent Cre 
activity. No pancreatic and hindbrain nuclear-mCherry signals were detected in control 
larvae (a1-e1, f1-h1). CFP signal (cyan) could be detected ubiquitously (c1, f1, c2, f2). 




2.3.2 The early ptf1a lineage has limited contribution to non-acinar cell fates in the 
zebrafish pancreas 
The expression of ptf1a is first detectable around 32 hours post fertilization (hpf). 
It has been reported that ligand-mediated recombination could be detected as early as 2 
hours post 4-OHT treatment in the CreERT2 transgenic zebrafish system (Hans et al., 2009). 
We treated the lineage-tracing fish with 4-OHT at 30-54 hpf in an effort to label the earliest 
pool of ptf1a-expressing pancreatic progenitor cells (Fig. 2.2A). We subsequently imaged 
the fish at 6 dpf, when pancreatic architecture is fully formed.  
To allow for the correct interpretation of results, we carefully evaluated the 
tamoxifen-independent recombination (leakage) of the system. We counted the total 
number of cells undergoing tamoxifen-independent recombination among 32 fish that had 
not been treated with 4-OHT. In the absence of 4-OHT, an average of 19 (±10) cells per 
fish were observed to have nuc-mCherry signal. To be noted, this is an estimate of the 
highest level of leakage, since we only included fish from which we observed leakage 
events. All of the cells that had recombination events in the absence of 4-OHT treatment 
displayed the morphology of pancreatic acinar cells. In comparison, among 32 fish that had 
been treated with 4-OHT, there were on average 377 (± 82) lineage labeled cells per fish. 
In brief, leakage cells were only a small proportion of the total labeled cells (<5%), and 
were limited to the acinar lineage. We therefore concluded that our study would not be 
significantly confounded by tamoxifen-independent recombination, especially as it related 
to the contribution of ptf1a-expressing cells to non-acinar lineages.  
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We next set out to evaluate the contribution of ptf1a–expressing progenitor cells to 
different pancreatic lineages. We observed broad contributions to the acinar cell lineage, 
confirming that ptf1a–expressing progenitor cells represent the major and perhaps the 
exclusive source of these cells. We also observed lower magnitude contributions to the 
PNC and endocrine (principal islet) cell lineages. For the 36 fish we examined, 26 of them, 
72% of the total number of fish, did not have any detectable contribution of the ptf1a-
expressing lineage to PNCs (Fig. 2.2B; Fig. 2.5F). For the remaining 10 fish, there were 
on average 8 ptf1a-lineage-labeled cells traced into PNCs (Fig. 2.2C; Fig. 2.5F). This 
constituted around 5.8% of the total number of PNCs at 6 dpf, which on average were 137 
cells per fish (8/137=5.8%). We subsequently surveyed the ptf1a lineage contribution to 
endocrine cells in the principal islet. At 6 dpf, the principal islet contains endocrine cells 
directly descended from the dorsal bud as well as cells differentiated during the secondary 
transition (Biemar et al., 2001; Hesselson et al., 2009). For the 21 larvae we assessed, 11 
of them, which represented 52% of the total number of fish, did not have any ptf1a lineage-
labeled cells traced into the principal islet (Fig. 2.2D; Fig. 2.5G). For the 10 remaining 
larvae where we did observe contributions from ptf1a-expressing progenitors to the 
endocrine lineage, with an average 3.4 lineage labeled cells observable in the principal islet 
(Fig. 2.2E; Fig. 2.5G). This represents 10% of the endocrine population at 6 dpf, which 
consists of, on average, 34 cells per principal islet (3.4/34=10%). The large variation of 
cell counting results in different larvae likely reflected the underlying population 




Figure: 2.2. Early ptf1a lineage has limited contribution to PNCs and endocrine 
cells. 
(A) Experiment setup. 4-OHT treatment was between 30-54h and larvae were fixed for 
image analysis at 6dpf. (B-E) In all the panels, ptf1a lineage is indicated by nuclear 
mCherry expression (red). (B) In the majority of pancreata, the ptf1a lineage and PNCs do 
not have overlaps. Immunofluorescent staining for Nkx6.1 (green) labels PNCs. (C) In 
some pancreata, ptf1a lineage cells are traced into PNCs. Arrows point to colabeling 
events. Nkx6.1, green. (D) In the majority of pancreata, the ptf1a lineage does not trace 
into endocrine. ptf1a:GFP transgene (green) shows current expression of ptf1a, which, at 6 
dpf, is limited to acinar cells.  Insulin (Ins) and Glucagon (Gluc), white. (E) In a few 
pancreata, some of the ptf1a lineage cells overlap with signals from  the ins:nuc-GFP 




2.3.3 The ptf1a lineage contributes to endocrine cells in juvenile and adult zebrafish  
We pulsed 4-OHT from 30-54 hpf, and further traced the ptf1a lineage into juvenile 
and adult fish to assess its contribution during later morphogenesis events. (Fig. 2.3).  
In 4-OHT treated fish, at 30 dpf, we saw widespread lineage labeling of acinar cells.  
In addition, we noted a contribution of ptf1a-expressing progenitors to endocrine cells 
within secondary islets. Interestingly, for some of the secondary islets in which we 
observed ptf1a lineage labelling, almost all endocrine cells within the islets were labeled 
(Fig. 2.3A, B). We theorized that the ptf1a lineage gave rise to the progenitors of those 
secondary islets, which subsequently had gone through a clonal expansion process to form 
the secondary islet clusters.  
Similarly, in the adult pancreas, we observed isolated as well as clustered ptf1a 
lineage labeled cells located with the islet that were positive for hormone markers (Fig. 
2.3C, D). We believe these ptf1a labeled endocrine cells emerged during early pancreas 




Figure: 2.3. Early ptf1a lineage contributes to seconary islet and adult endocrine 
cells.  
(A) Experiment setup for lineage analysis in juvenile fish. (B) A representative section 
from 30 dpf juvenile lineage-tracing fish. ptf1a lineage is labeled by nuclear mCherry 
expression (red). The secondary islets (outlined) contain a cluster of ptf1a lineage labeled 
cells. Transgenic marker neuroD:GFP (green) labels all endocrine cells. (C) Experiment 
setup for lineage analysis in adult fish. (D) A representative section from adult lineage-
tracing fish. ptf1a lineage is labeled by nuclear mCherry expression (red). Some of the 
endocrine cells have lineage label. Endocrine population is labeled by the mix of 
antibodies against Insulin (Ins), Glucagon (Gluc) and Somatostatin (Sst), white. ptf1a:GFP  
transgene (green) marks for acinar cells. DAPI, blue. Scale bar, 50 µm. 
 
2.3.4 ptf1a lineage contributes to endocrine β-cell regeneration 
Having assessed the ptf1a lineage during normal pancreas development, we 
proceeded to determine whether it would contribute to β-cell regeneration as well. To this 
end, we employed a well-established cell-ablation NTR system to remove β cells. The 
enzyme nitroreductase (NTR), encoded by the bacterial gene nfsb, can convert prodrugs 
such as metronidazole (Met) to cytotoxins. In our system, we expressed nfsb gene under 
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the control of insulin promoter. Subsequently, upon administration of Met, the insulin 
secreting β cells would be destroyed, with cell death occurring within 6 hours post Met 
treatment. β-cell regeneration could be observed within 36 hours after Met removal 
(Pisharath et al., 2007). We crossed ptf1a:creERT2; ubi:loxp-CFP-loxp-nuclear-mCherry 
fish with  sst:CFP; ins:dsYFP-2TA-nsfB fish (Fig. 2.4A).  
We treated the resulting triple transgenic fish with 4-OHT from 30-54 hpf and 
applied Met from 82-106 hpf (Fig. 2.4B). In the control pancreata, YFP-expressing β cells 
form a compact inner core, intermingled with somatostatin-secreting δ cells and surrounded 
by other endocrine cell types (Fig. 2.4C). In the Met treated pancreata, much weaker YFP 
signals were detected within the principal islet (Fig. 2.4D). Some cells contained 
aggregates with high YFP fluorescence intensity. However, these cells were located out of 
the boundary of the principal islet and had rounded up, indicating that they were 
undergoing apoptosis (Fig. 2.4D). We assessed β-cell regeneration at 6 dpf, around 48h 
after Met removal. At this time point, β cells started to regenerate but there was still a 
distinct reduction of β-cell numbers in the Met-treated fish (Fig. 2.4E, F). Interestingly, we 
observed that ptf1a lineage contributed to a fraction of the newly generated β cells (Fig. 
2.4F). The level of contribution, however, was similar to the control pancreas (Fig. 2.4G), 











Figure: 2.4. The ptf1a lineage contributes to β-cell regeneration.  
(A) The triple transgenic line we utilized in the experiment. Besides the ptf1a lineage 
tracing constructs, the fish carries the nfsB transgene construct intended for β-cell ablation. 
Insulin promoter drives expression of destabilized YFP (dsYFP) and nfsB. somatostatin 
(sst) promoter drives the expression of CFP. (B) Experiment setup. (C) In control fish that 
does not have Metronidazole (Met) treatment, the principal islet has compact architecture. 
The Insulin-secreting β cells can be find in the inner core of the principal islet interspaced 
with δ cells. Insulin (Ins), yellow. Somatostatin (Sst), cyan. Nuclei are labeled by DAPI 
(blue). Notice that the signal from somatostatin expressing cells can be distinguished from 
the ubiquitin CFP signal due to the higher signal intensity from the former promoter. (D) 
Immediately after 24h of Met treatment. There is only residues of insulin signal. Some cells 
have higher than normal Insulin expression. They are apoptotic cells that are generally 
located on the peripheral of principal islet. Insulin (Ins), yellow. Somatostatin (Sst), cyan. 
DAPI, blue. (E, F) ptf1a lineage is labeled by nuclear mCherry expression (red). 48 h after 
removal of Met. (E) In untreated fish, there are rare ptf1a lineage cells traced into principal 
islet. Insulin (Ins), yellow. Somatostatin (Sst), cyan. (F) In the Met treated fish, two 
regenerated β cells have ptf1a lineage label. Insulin (Ins), yellow. Somatostatin (Sst), cyan. 
(G) Quantification of ptf1a lineage labeled cells that are traced into endocrine. There is no 























2.3.5 The ptf1a lineage has increased plasticity in the ptf1asa126/wt heterozygous fish 
In the mouse, pancreatic cells with different Ptf1a gene dosages seem to have 
altered cell fates (Fukuda et al., 2008; Pan and Wright, 2011). During early mouse pancreas 
development, it has been shown that intermediate expression of Ptf1a marks multipotent 
progenitor cells, whereas higher Ptf1a expression levels are observed in pancreatic 
progenitors undergoing restriction towards an acinar cell fate (Pan et al., 2013). Similarly, 
in zebrafish, studies have shown that reduced levels of ptf1a seem to promote endocrine 
differentiation (Dong et al., 2008). Even in the adult fish, reduction of the ptf1a activity 
induces the expression of endocrine-specific genes in the mature acinar cells (Hesselson et 
al., 2011). To formally characterize the ptf1a lineage allocation under conditions of reduced 
ptf1a dosage, we took advantage of the ptf1asa126/wt mutant fish generated by the Sanger 
Zebrafish Mutation Project (Kettleborough et al., 2013). The ptf1asa126 allele contains a 
nonsense mutation within exon1 of the ptf1a coding region (Fig. 2.5A). This mutation is 
predicted to result in either the expression of a truncated protein or the induction of 
nonsense-mediated decay (NMD) (Randlett et al., 2013).  
We first characterized pancreatic morphology in ptf1asa126/wt heterozygous and 
ptf1asa126/sa126 homozygous fish. Homozygous ptf1a mutations phenocopied the previously 
reported ptf1a morpholino phenotype (Fig. 2.5B, C) (Lin et al., 2004). At 5 dpf, 
ptf1asa126/sa126  fish did not have an exocrine pancreas, as assessed by ptf1a:GFP transgene; 
whereas the principal islet appeared normal (Fig. 2.5B, C). In contrast, ptf1asa126/wt 
heterozygous fish displayed normal pancreatic morphology at 5dpf.  These data are 
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consistent with the prediction that the pf1asa126 mutation represents a hypomorphic or 
functionally null allele.  
We next proceeded to perform lineage tracing experiments in ptf1asa126/wt 
heterozygous fish. Intriguingly, under this condition with reduced ptf1a dosage, more ptf1a 
lineage labeled cells were traced into PNCs and the principal islet (Fig. 2.5D-G). For the 
29 fish we examined, 10 of them, 10/29=34% of the total number of fish, did not have any 
ptf1a-lineage labelling in PNCs. This percentage is lower than in the wildtype condition, 
where the corresponding percentage is 72% (Fig. 2.5F). Among the fish where we observed 
ptf1a-lineage labelling in PNCs, on average 17 cells per pancreas, around 13.5% of the 
total number of PNCs, were labeled by ptf1a lineage (Fig. 2.5F). The level of contribution 
of ptf1a lineage to PNCs in the ptf1asa126/wt ptf1a heterozygous fish is significantly higher 
compared with wildtype.  
Similarly, we observed that in the ptf1asa126/wt fish, there was a lower percentage of 
fish in which we did not observe ptf1a lineage-labeled cells within the principal islet (22% 
compared with 52% of fish in the wildtype ptf1a condition) (Fig. 2.5G). At the same time, 
there was a higher percentage of endocrine population labeled by ptf1a lineage (18.9% 
compared with 10% in the pancreata of ptf1a wildtype).  All of these differences were 
statistically significant. At the same time, the total number of PNCs and the total area 
occupied by the endocrine population showed no difference between wildtype and 
ptf1asa126/wt heterozygous pancreas (Fig. 2.5H, I). Furthermore, there was no correlation 
between the number of ptf1a lineage labeled cells traced into PNCs and the total number 
of PNCs (data not shown). These data suggest that haploinsufficiency for ptf1a promotes 
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enhanced contribution of ptf1a-expressing pancreatic progenitors to non-acinar cell fates, 
with higher level of regulatory mechanisms acting to regulate the actual number of PNCs 






Figure: 2.5. The ptf1a lineage displays enhanced plasticity in the ptf1asa126/wt fish. 
(A) The Sanger ptf1asa126 allele. This mutant allele has an A to T transition in the first exon 
of ptf1a, introducing a premature stop codon. The ptf1asa126 allele either encodes a truncated 
protein or induce nonsense mediated decay. (B) Wildtype d5 larvae, with ptf1a:GFP 
(green) transgene marks for exocrine pancreas, and ins:mCherry (red) transgene marks for 
β cells within the principal islet. (C) ptf1asa126/sa126 homozygous fish do not have exocrine 
pancreas. Notice the hindbrain and retina signal of ptf1a:GFP are preserved. (D, E) ptf1a 
lineage is labeled by nuclear-mCherry expression (red). (D) In the ptf1asa125/wt fish, more 
lineage labeled cells can be traced into PNCs. Nkx6.1 (green) is a marker for PNCs. Arrows 
point to colabling events. (E) In the pf1asa126/wt fish, more lineage labeled cells can be traced 
into endocrine. neuroD:GFP transgene marks for endocrine population. Principal islet is 
outlined. Notice the mCherry signal within the principal islet. (F) Quantification of ptf1a 
lineage-labeled cells contributing to PNCs. (G) Quantification of ptf1a-lineage labeled cells 
contributing to endocrine. (H) The total number of PNCs and (I) the whole endocrine area 














2.3.6 Further cell fate conversion in the ptf1asa126/sa126 homozygous fish  
In homozygous ptf1asa126/sa126 fish, there are no detectable acinar cells and no 
secondary islets (Fig. 2.5C). Nonetheless, even in the absence of morphologically 
discernible exocrine pancreas, we still observed a ptf1a lineage-labeled population in the 
region of the intestinal bulb. In order to characterize the identify of these cells, we 
performed immunolabelling using the 2F11 antibody that recognizes enteroendocrine cells, 
intrahepatic bile ducts, gall bladder, hepatopancreatic ducts and PNCs (Dong et al., 2007). 
2F11 antibody staining indicated that some of the ptf1a lineage labeled cells were located 
within the gall bladder (Fig. 2.6A, B). Moreover, in the homozygous mutant fish, ptf1a 
lineage labeled cells could also be detected in the PNCs as well as the principal islet (Fig. 
2.6C, D). Of note, in the ptf1asa126/sa126 fish, PNCs were properly specified (Fig. 2.6D). This 
observation was consistent with the notion that ptf1a lineage and PNCs are independently 
specified (Wang et al., 2011). However, in the homozygous mutant fish, PNCs remained 
as a cluster of cells adjacent to the principal islets, and the total number of PNCs was 
significantly reduced (Fig. 2.6D). These data suggest that ptf1a lineage-derived acinar cells 
may provide a supporting cellular framework required for the normal proliferation and 
migration of PNCs and establishment of the ductal network. The reduced number of PNCs 
is not likely to reflect a direct requirement for ptf1a in a fraction of PNCs, since under 
wildtype ptf1a conditions, there were only around 5% of PNCs were labeled by ptf1a 
lineage. Alternatively, other cell types mediating the effect of acinar cells to PNCs might 









Figure: 2.6. ptf1a lineage analysis in the homozygous ptf1asa126/sa126 fish.  
In all the panels, ptf1a lineage labeled cells are shown in red. (A) In wildtype zebrafish, 
ptf1a lineage labelling can be observed in the hindbrain and pancreas (A’). A’’ is a zoomed-
in, 3D-reconstructed view of the boxed region in A’. 2F11 (purple) labels gall bladder, 
liver, pancreatic PNCs, and some structure in the gut bulb. Notice that no lineage labeled 
cells can be observed in the gall bladder. (B) In the ptf1asa126/sa126 fish, there is no exocrine 
pancreas structure. Some of the lineage labeled cells can be observed in the wall of gall 
bladder. In addition, there is another unidentified population right next to the gall 
bladder. B’’ is a zoomed-in, 3D-reconstructed view of the boxed region in B’. 2F11, purple. 
The gall bladder is also enlarged in the homozygous mutant fish compared with wildtype. 
Also, in the ptf1asa126/sa126 fish, there is still hindbrain lineage labelling. (C-D) insulin, 
glucagon, somatostatin (green) labels endocrine population. Nkx6.1 (purple) labels PNCs. 
(C) In the wildtype zebrafish pancreas, the majority of lineage labeled cells are in the 
acinar population. PNCs can be observed in the middle of the pancreas. (D) In the 
homozygous ptf1a mutant fish, the number of PNCs is reduced and they do not migrate. 
ptf1a lineage labeled cells can be detected in the principal islet and some of the PNCs. gb, 















In the present study, we generated a new ptf1a fate-mapping fish and carried out 
formal ptf1a lineage analysis in developing, regenerating and ptf1a-deficient pancreas. We 
observed a major contribution of the ptf1a progenitor lineage to later appearing acinar cells, 
and a minor contributions to PNCs and endocrine cells during development. The ptf1a 
lineage also contributed to β cells during regeneration. Furthermore, different dosages of 
ptf1a influenced the magnitude of non-acinar lineage contributions. In heterozygous 
ptf1asa126/wt fish, we observed a larger contribution from the ptf1a progenitor lineage to the 
PNC and endocrine compartments. As in the mouse, a complete absence of ptf1a leads to 
incorporation of ptf1a-expressing cells into the gall bladder and other foregut tissues.  
2.4.1 Clonal expansion of secondary islets  
In the secondary islets where we observed ptf1a lineage labelling, there was always 
a cluster of lineage traced cells detected. The low probability of ptf1a lineage labelling in 
the endocrine population made it almost certain that this clustered labelling pattern 
originated from clonal expansion events. Presumably some of the secondary islets 
originated from single ptf1a positive progenitors. Subsequently, theses progenitor cells 
undergo clonal expansion. This is consistent with previous studies showing that newly 
generated secondary islets arise from single cells along the Notch-expression domain, and 
that these cells are highly proliferative (Parsons et al., 2009).  
2.4.2 ptf1a lineage and Notch-responsive lineage  
We used Nkx6.1 as a surrogate marker for PNCs in the current study. We observed 
that in the zebrafish pancreas, immunofluorescent labelling for Nkx6.1 completely 
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overlaps with PNCs marked directly by the transgene TP1:eGFP (Huang et al., 2014). In 
mouse, it has been shown that Ptf1a and Nkx6.1 reciprocally repress the alternative lineage, 
with the former directing cellular programming towards the acinar fate; whereas the latter 
promotes an endocrine fate (Schaffer et al., 2010). We believe that the same mechanism is 
applicable in the zebrafish pancreas. Specifically, we observed that in the ptf1asa126/wt fish 
where ptf1a dosage is partially reduced, there was a significantly greater ptf1a lineage 
contribution to PNCs. PNCs have been shown to be the precursors of endocrine population 
in zebrafish and inhibition of Notch signaling in PNCs leads to endocrine differentiation 
(Wang et al., 2011). At present, however, it is unclear whether the increased contribution 
of the ptf1a lineage to the endocrine lineage in the ptf1a heterozygous fish went through 
an intermediated PNC-stage or direct transdifferentiation.  
2.4.3 Different levels of ptf1a regulate the multi-lineage potential of ptf1a-expressing 
progenitors 
With very low levels of ptf1a in the ptf1asa126/sa126 fish, endocrine cell differentiation 
still occurred and the principal islet structure was maintained. This result is similar to 
previously reported ptf1a morpholino phenotype (Lin et al., 2004), but different from 
observations in human and mouse in which low level of ptf1a reduces the endocrine cell 
numbers and alters their distribution (Burlison et al., 2008; Fukuda et al., 2008; Stoffers et 
al., 1997). This may reflect the different developmental programming of zebrafish pancreas 
(Tiso et al., 2009). In zebrafish, the early endocrine cells within the principal islet arise 
from a very early primary transition. At the time when these cells are specified, ptf1a has 
not started to be expressed. The other likely scenario is that in both ptf1a morphant and 
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ptf1asa126/sa126 homozygous fish, there still exists some expression of ptf1a to support the 
proper endocrine lineage differentiation. This possibility is supported by a recent study on 
the requirement of ptf1a expressing cells in formation of retinal neuropil (Randlett et al., 
2013). They demonstrated that the combination of ptf1asa126/sa126 alleles together with a 
ptf1a translational blocker morpholino are required to reveal the ptf1a null phenotype 
(Randlett et al., 2013).   
In the Sanger homozygous fish, the ptf1a lineage converted to gall baldder and 
other non-pancreatic fates. This cell-fate conversion is exactly the same as what was 
observed in mice (Burlison et al., 2008; Fukuda et al., 2008). 
Overall, it is apparent from the current work that different cellular fates require 
different threshold levels of ptf1a. Further studies are needed to characterize the 
mechanisms that are responsive to different levels of ptf1a. Our findings have provided an 
important understanding on the mechanisms of pancreatic development in zebrafish, which 
in turn will have important clinical implications, especially in guiding the differentiation 















Chapter 3. Progenitor cells in adult mouse pancreas 
3.1 Introduction 
Mesenchymal stem cells (MSCs) have been isolated from a variety of tissues, 
including bone marrow, peripheral blood, adipose tissue, lung, etc. (Lama et al., 2007; 
Pittenger et al., 1999; Zuk et al., 2002; Zvaifler et al., 2000). MSCs can readily attach to 
plastic surfaces and expand rapidly in vitro (Beyer Nardi and da Silva Meirelles, 2006). 
They are capable of differentiating into multiple lineages, including osteoblasts, 
adipocytes, and chondrocytes (Beyer Nardi and da Silva Meirelles, 2006; Dominici et al., 
2006; Pittenger et al., 1999).  MSCs have shown great therapeutic potential. They not only 
directly contribute to the regeneration of tissues of mesoderm, ectoderm and endoderm 
lineages (Chamberlain et al., 2004; Ortiz et al., 2003; Prabhakaran et al., 2009), but also 
secrete salutary paracrine signals (Gnecchi et al., 2005), modulate the host immunological 
response (Aggarwal and Pittenger, 2005), and provide supportive niche (Chen et al., 2002) 
to benefit transplant recipients. 
In the pancreas, there are two other stromal cell types that have been found to have 
particularly interesting properties: pancreatic stellate cells (PSCs) (Apte et al., 1998; 
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Bachem et al., 1998) and pericytes (Crisan et al., 2008).  PSCs are the major source of 
fibrosis in chronic pancreatitis and pancreatic cancer. They have evolved to be a promising 
target for pancreatic cancer therapy. PSCs contain vitamin A droplets during quiescence. 
When activated, they lose their vitamin A droplets, start to express α-smooth muscle actin 
(α-SMA) and other extracellular matrix (ECM) proteins. PSCs express specific markers 
such as desmin, vimentin, nestin, and glial fibrillary acidic protein (GFAP). (Apte et al., 
2004; Casini et al., 2000; Haber et al., 1999; Masamune et al., 2009; Omary et al., 2007). 
Pericytes, on the other hand, have long cytoplasmic processes, wrap around endothelial 
cells and express molecular markers such as desmin, α-SMA, platelet-derived growth 
factor-B (PDGF-B), and NG2, a proteoglycan associated with pericytes during vascular 
morphogenesis (Hellstrom et al., 1999; Nehls and Drenckhahn, 1991; Ozerdem et al., 
2001). Similar to MSCs, pericytes have been shown to have multilineage differentiation 
potential (Crisan et al., 2008). Furthermore, pericytes exhibit abnormalities in pancreatic 
cancer (Morikawa et al., 2002). 
The initial plan of the current study was to identify and thoroughly characterize 
adult pancreatic progenitor cells. Adult pancreatic progenitor cells, if they exist, would 
promise a giant leap in the generation of new β cells for cellular replacement therapy for 
the treatment of diabetic patients (Bouwens et al., 2013). Putative progenitor cell 
populations have been reported among acinar cells, ductal cells, centroacinar cells, as well 
as endocrine cells (Choi et al., 2004; Inada et al., 2008; Minami et al., 2005; Rovira et al., 
2010; Seaberg et al., 2004; Smukler et al., 2011; Xu et al., 2008; Zulewski et al., 2001).  
However, these reports have largely been based on in vitro culture and they suffer from 
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incomplete lineage characterization in vivo. Hence we do not know for sure where these 
progenitor cells originate from and what their endogenous functions are. The jury is still 
out concerning whether there exists in adult pancreatic tissue any resident progenitor cells. 
To explore new populations of progenitor cells in pancreas, we evaluated markers that have 
been reported to be enriched in stem /progenitor cells within pancreas and other tissue – 
both in the normal as well as neoplastic tissues undergoing cancer initiation and 
progression. These markers include: Aldefluor activity (Ginestier et al., 2007; Rasheed et 
al., 2010; Rovira et al., 2010), CD24 (Al-Hajj et al., 2003; Li et al., 2007), CD44 (Al-Hajj 
et al., 2003; Li et al., 2007; Prince et al., 2007), CD49f (Sugiyama et al., 2007), CD133 
(Prominin-1) (O'Brien et al., 2007; Ricci-Vitiani et al., 2007; Singh et al., 2004; Sugiyama 
et al., 2007), c-kit (Ellison et al., 2013; Esposito et al., 2002), c-Met (Li et al., 2011), 
EpCam (Gires et al., 2009; Li et al., 2007; Munz et al., 2009), and Sca-1 (Holmes and 
Stanford, 2007). Corresponding populations of cells from adult mouse pancreata were 
isolated and cultured in sphere-forming condition (Rovira et al., 2010; Visvader and 
Lindeman, 2008; Wang et al., 2013). In doing so, we identified a unique type of stromal 
cell residing in the adult mouse pancreas. These cells were characterized by high Aldefluor 
activity (A+) and Sca-1 positivity (Sca-1+). They had long cytoplasmic processes and were 
found adjacent to blood vessels. They shared some features with mesenchymal stem cells, 
such as their sphere-forming capability, plastic affinity and multi-lineage differentiation 
potential. However, they did not have all the canonical MSC surface markers, such as 
CD105 and CD90. Similarly, A+Sca-1+ cells have some characteristics of stellate cells and 
pericytes, but they did not completely fit into the profiles of either category of cells. A+Sca-
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1+ cells were upregulated during cerulein-induced acute pancreatitis. Cytokine arrays 
revealed that A+Sca-1+ cells secreted factors similar to embryonic pancreatic 
mesenchyme. We, therefore, propose that A+Sca-1+ cells function as a niche to maintain 
normal pancreas homeostasis. Their mesenchymal differentiation potential in vitro and 
their upregulation during pancreatitis imply that they may also play a role in fibrosis during 
pathological change of pancreas. 
Contributions: Dr. Meritxell Rovira made the initial observation that Aldefluor 
positive cells had increased sphere-forming capability. I subsequently repeated this result 
and further advanced the analyses as noted below. The following chapter represents my 
own work.  
3.2 Materials and Methods 
Sections 3.1.1 to 3.1.2.6 are adapted from Springer Methods in Molecular Biology, 
980, 2013, pp 281-290, Sphere-forming assays for assessment of benign and malignant 
pancreatic stem cells, Yue J. Wang, Jennifer M. Bailey, Meritxell Rovira, Steven D. Leach, 
figure number: 1; with kind permission from Springer Science and Business Media (Wang 
et al., 2013). 
3.2.1 Materials 
1. Isofluorane. 
2. Hank’s balanced salt solution (HBSS) w/o Calcium and Magnesium (Gibco 
14175-095). 
3. Phosphate Buffered Saline (PBS). 




7. Trypan blue. 
8. Aldefluor kit, STEMCELL Technologies 01700 
9. Pancreatic stem cell culture medium 
Basal medium is DMEM/F12 (1:1) Gibco 11039. This medium is supplemented 
with: 
FBS, Gibco 
NEAA, Gibco 11140 
N2, Stemcell Technologies 07152 
B27, Invitrogen 17504-044 
LIF, Stemcell Technologies 02740a 
EGF, Peprotech AF-100-15 
FGF2. Invitrogen 13256-029 
Equipment 
1. Surgical tools. 
2. Polypropylene mesh (100 μm and 500 μm). 
3. 37℃ waterbath.  
4. Inverted microscope. 
5 Haemocytometer. 




Carry out all procedures when possible in a sterile hood to minimize chances of 
contamination of cultures.  
3.2.2.1 Media preparation for culturing adult mouse pancreas 
1. 50ml HBSS with 5%FBS. Store on ice. 
2. 10ml HBSS. Store on ice. 
3. 10ml PBS with 5%FBS. Store on ice. 
4. Pre-warm 5ml Trypsin/EDTA 0.05% in 37℃ in water bath. 
5. 10ml Collagenase P, 1-1.5 mg/ml in HBSS. 
6. Pancreatic stem cell culture medium        
                      Component        Volume (μl) Final concentration 
DMEM/F12  Add up to 50ml 
FBS 1500  3% 
Non Essential Amino Acid 500  1× 
Pen/Strep 500  100 U/ml 
N2 Supplement 500  1× 
B27 Supplement 1000  1× 
EGF  20ng/ml 
FGF2  20ng/ml 
LIF  10ng/ml 




*The activity of the growth factors decreases with time. It is preferred to prepare medium 
fresh each time. Do not keep media longer than 7 days when stored at 4℃. 
3.2.2.2 Single cell isolation from adult mouse pancreas. 
1. Anesthetize the 6-12 week old adult mouse with isofluorane. 
2. Dissect the pancreas and transfer it to a petri dish with HBSS on ice. Wash off 
any blood.   
3. Transfer pancreas to an empty petri dish and inject 1 ml of Collagenase P at 
various points with 1 ml insulin syringe and 28 gauge needle.  
4. Mince the pancreas into 1-5mm pieces using scissors and transfer everything into 
a 50 ml falcon tube with 4 ml of Collagenase P (1-1.5 mg/ml). 
5. Place the 50ml tube in a 37℃ water bath. Shake gently every 3 min for 11 min 
total. The digestion progression can be monitored by sampling and observation 
under an inverted microscope. Digestion should stop when no big tissue chunks 
remain. 
6. Stop the reaction by placing the tube on ice and adding 5ml of HBSS with 5% 
FBS. 
7. Centrifuge at 720 x g for 2min at 4℃. Decant the supernatant and resuspend the 
pellet with 5ml of cold HBSS with 5% FBS. Centrifuge at 720 x g for 2min at 4℃. 
8. Decant the supernatant and resuspend the pellet with 5ml cold HBSS. Filter 
through a 500 μm mesh. Wash the tube with 5ml cold HBSS and filter into the same 
tube. Centrifuge at 720g for 2 min at 4℃. 
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9. Decant the supernatant and trypsinize with 0.05% Trypsin/EDTA for no longer 
than 5min in a 37℃ water bath.  This is the most critical step. 
10. Stop the reaction by placing the tube on ice and adding 5ml of cold PBS with 
5% FBS. 
11. Centrifuge at 720 x g for 2min at 4℃. Decant the supernatant and resuspend the 
pellet with 5ml of cold PBS with 5% FBS. Centrifuge at 600 x g for 3 min at 4℃. 
12. Decant the supernatant and resuspend the pellet with 5ml cold PBS with 5% 
FBS. Filter through a 100 μm mesh. Wash the tube with 5ml cold PBS with 5% 
FBS and filter into the same tube. To analyze cell viability and to calculate the 
number of cells, take 10 μl sample into 90 μl of Trypan blue. Centrifuge the rest at 
600 x g for 3 min at 4℃. 
3.2.2.3 Labeling of pancreatic cells with Aldefluor reagent. 
1. Calculate the viable cell concentration with a hemacytometer. Viable cells are 
determined by Trypan Blue dye exclusion. 
2. Re-suspend cells with Aldefluor buffer at 1 million cells per ml.  
3. Take out 500 μl cells as nonstaining control. 
4. Prepare a 15 ml conical tube labeled with DEAB. Add 5 μl of DEAB into this 
tube. Fasten the cap to prevent evaporation.  
5. Add 5 μl of Aldefluor substrate per each ml of cells. 
6. Immediately transfer 500 μl of cells from step 5 into the tube labeled with DEAB. 
7. Put the nonstaining tube, the Aldefluor tube and DEAB tube in a 37℃ cell culture 
incubator and incubate for 40-50 min. 
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8. To stop the reaction, put the sample on ice. 
9. Centrifuge at 600 x g for 3min at 4℃. 
10. Decant the supernatant. Re-suspend the cell pellets with PBS, 5%FBS and filter 
with a 40 micron cell strainer.  
3.2.2.4 Flow cytometry 
Set up proper gates according to the instructions in Aldefluor kit. 
Sort onto a plate or into 5ml tubes.  Collect A+ and A- populations. 
3.2.2.5 Pancreatosphere culture 
Seed the cells (6000 cells/ml) on ultra-low attachment plates. Incubate at 37°C with 
95% air and 5% CO2. Culture cells for 5-7 days. 
3.2.2.6 Preparation of whole-mount pancreatosphere for immunofluorescent 
labeling 
1. Transfer the culture medium with pancreatospheres to 15ml conical tube. Allow 
the spheres to settle by gravity.  
2. Remove the supernatant without disturbing the bottom and mix gently with 4% 
PFA. Fix the spheres for 20min at room temperature. 
3. Remove the supernatant and rinse with 10ml of PBS. Allow the spheres to settle. 
4. Remove the supernatant and add 5ml of PBS with 0.2%Triton and 10%FBS. 
Block for 1h at room temperature. 
5. Remove the supernatant and add primary antibody. Incubate at 4°C overnight. 
6. Directly add 10ml of PBST with 10%FBS into the sphere tube the next day.  
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7. Allow spheres to settle. Take out the supernatant and wash the spheres once with 
PBST with 10% FBS. 
8. Remove the supernatant and add seconary antibody. Incubate at room 
temperature for 2 hrs. 
9. Directly add 10ml of PBS into the sphere tube. 
10. Allow the spheres to settle. Take out the supernatant and wash the spheres once 
with PBS. 
11. Take out as much of the supernatant as possible. Add DAPI into the sphere tube. 
12. Take out the medium with spheres and add it onto a slide circled with PAP pen. 
Wait until the spheres settle onto slides. Under the microscope, try to find the 
spheres and remove the surrounding medium.  
13. Find spheres under a confocal microscope using the DAPI channel. 
3.2.2.7 In vitro differentiation of mesenchymal stem cells 
The mutilineage differentiation of A+Sca-1+ cells was carried out following the 
protocol available from R&D systems, Catolog #SC010. 
3.2.2.8 Cerulein induced acute pancreatitis 
Acute pancreatitis was induced by administration of 6 hourly intraperitoneal 
injections of cerulein 50 µg/kg over 2 consecutive days. At indicated time points, 
mice were sacrificed and acinar cells were prepared for live labeling. All procedures 
were performed under the approval of the Johns Hopkins University School of 
Medicine Animal Care and Use Committee guidelines. 
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3.2.2.9 E12.5 pancreatic dorsal buds culture and microinjection 
E12.5 dorsal pancreatic buds were isolated as previously described (Esni et al., 
2005). Immediately after dissection, the dorsal buds were injected with Aldefluor-
positive or -negative cells freshly sorted from adult mTmG transgenic mouse 
pancreas. They were subsequently cultured on top of MilliCell-CM insert, in RPMI 
medium + 10% FBS, with Penicillin and Streptomycin for 7 days. Standard 
fixation, OCT embedding and immunofluorescence were pursued.  
3.2.2.10 Cytokine array 
RayBio mouse cytokine antibody array 3 (G-Series) was carried out per the 
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3.3 Results 
3.3.1 Aldefluor (+) Sca-1(+) population in adult mouse pancreas 
In a search for potential adult pancreatic progenitor cells, we first evaluated a 
number of stem cell markers that have been reported in the literature for a variety of tissues. 
These included: Aldefluor activity, CD24, CD44, CD49f, CD133, c-kit, c-met, EpCam, 
PDGFR-B, and Sca-1. Interestingly, all of the markers under assessment were found to be 
expressed by some cells inside the pancreas either by flow cytometry and/or by 
immunofluorescence.  
Sphere-forming assays are widely used in stem cell biology to assess the self-
renewal and differentiation potential of a particular cell type (Pastrana et al., 2011). We 
adapted a protocol similar to that reported for the generation of neurospheres to generate 
pancreatospheres (Reynolds and Weiss, 1992; Rovira et al., 2010; Wang et al., 2013). 
Corresponding populations positive for single marker and combinations of markers were 
isolated by flow cytometry and cultured at clonal density (6,000~10,000 cells/ml of media) 
in suspension in the sphere-forming media. Among all the markers we tested, the 
combination of Aldefluor positive (A+) and Sca-1 positive (Sca-1+) highly enriched a 
sphere-forming population (Fig. 3.1). The Aldefluor reagent offers an approach to isolate 
 
58 
stem/progenitor cells based on their high expression of the enzyme aldehyde 
dehydrogenase (ALDH) (Corti et al., 2006; Ginestier et al., 2007; Storms et al., 1999). Sca-
1 (Ly-6 A/E) is a glycosyl phosphatidylinositol (GPI)-linked cell surface protein found on 
stem/progenitor cells in multiple tissues and organs including the hematopoietic system 
(Spangrude et al., 1988), mammary gland (Welm et al., 2002), myocardium (Oh et al., 









Figure 3.1: Aldefluor (+) Sca-1(+) population in the adult pancreas.  
(A) Gating of Aldefluor positive (A+) cells based on Aldefluor + DEAB negative control. 
(B) Aldefluor labels around 1% of total cells in the adult mouse pancreas acinar 
preparation. (C) Plot shows only the A+ cells. Among the A+ population, around 50% of 







3.3.2 Aldefluor (+) Sca-1(+) cells have unique features 
I performed live labelling and imaging of A+Sca-1+ cells. Light Collagenase P 
digestion would release the acini from the pancreatic parenchyma but maintain their 
organization. Subsequent Aldefluor reaction and whole mount cell-surface antibody 
labelling could be carried out on these intact acini. This procedure preserves the 
endogenous architecture formed by different pancreatic cell types. Confocal analysis 
showed that A+Sca-1+ cells had long cytoplasmic processes and were in close proximity 
to blood vessels (Fig. 3.2A). Apart from being Aldefluor and Sca-1 positive, this population 
of cells did not display positive staining of the endothelial cell marker (CD31) (Fig. 3.2A, 
A’), the epithelial cell maker (EpCam) (Fig. 3.2B, B’), the ductal cell marker (Dolichos 
biflorus agglutinin, DBA) (Fig. 3.2C, C’) or the pericyte marker (NG2) (Fig. 3.2D). RNAs 
were extracted from isolated A+Sca-1+ cells. qRT-PCR showed that A+Sca-1+ cells had 
high expression of vimetin and GFAP, which are known markers of stellate cells (Fig. 
3.2E). However, stellate cells are also high in nestin (Omary et al., 2007). On the contrary, 







Figure 3.2: The Aldefluor (+) Sca-1 (+) population has unique cellular features.  
(A, A’) A+Sca-1+ cells have long cytoplasmic processes and locate in proximity to blood 
vessel. Pictures shown are from live-labeling of collagenase digested acini. Aldefluor 
labeling is shown in green. Notice that there is background labeling in the acinar cells. A+ 
cells are defined as those cells with high Aldefluor signal, shown in bright green in all the 
panels. CD31 (red) labels endothelial cells. (B, B’) A+ cells are not epithelial cells. EpCam, 
purple, labels epithelial cells.  EpCam staining is absent in A+ cells. (C, C’) A+Sca-1+ cells 
are not ductal cells. DBA (red) labels pancreatic duct. Sca-1, white. (D) A+ cells are not 
pericytes. Pericytes are labeled by NG2 (white). They wrap around CD31+ (red) blood 
vessels and have distinct morphology compared with A+Sca-1+ cells. (E) qRT-PCR using 
mRNA isolated A+Sca-1+ cells show that this population has high expression of vimentin 
and GFAP, but lower expression of nestin compared with the bulk nonsorted population 















3.3.3 Aldefluor (+) Sca-1 (+) cells have mesenchymal stem cells properties 
A+Sca-1+ cells rapidly proliferated in vitro. As previously described, isolated 
A+Sca-1+ cells formed spheres in suspension within 5 days under sphere-forming 
conditions at clonal density (Fig. 3.1D, 3.3A). These spheres could be dissociated and 
passaged. Reseeded single cells from the primary spheres maintained the competence of 
forming secondary spheres (Fig. 3.3B). Furthermore, A+Sca-1+ cells adhered to plastic 
and could be passaged for multiple generations as attachment cultures. Under both 
suspension and plastic attachment culture conditions, A+Sca-1+ cells continued to express 
Vimentin and GFAP, but also turned on expression of Nestin and SMA (Fig. 3.3, C-E).  
Mesenchymal stem cells have been shown to be capable of adipogenic, osteogenic, 
and chondrogenic differentiation (Dominici et al., 2006). The multilineage differentiation 
potential of A+Sca-1+ cells were assessed using a Mouse Mesenchymal Stem Cell 
Functional Identification Kit (R&D Systems), according to the manufacturer's protocol. 
Strikingly, A+Sca-1+ cells also had the ability to differentiate into adipocytes, osteocytes 
and chondrocytes, establishing themselves as bona fide mesenchymal stem cells (Fig. 3.3, 




















Figure 3.3: Aldefluor (+) Sca-1(+) cells have mesenchymal stem cell properties. 
(A) Isolated A+Sca-1+ cells form mesenchymal spheres in clonal density. Cells in the 
sphere express mesenchymal markers Vimentin (green) and Nestin (red), but are mostly 
Ecad (pink) negative. (B) Primary spheres can be dissociated to form secondary spheres. 
(C) When cultured on plastic, A+Sca-1+ cells attach to plastic surface and maintain high 
levels of expression for vimentin (red). Nuclei are counterstained with DAPI (blue). (D, E) 
In attachment culture condition, A+Sca-1+ cells express GFAP (green) (D) and SMA 
(green) (E). (F-I) A+Sca-1+ cells have multilineage differentiation potential. (F) Under 
adipogenic condition, A+Sca-1+ cells are positive for Oil Red O.  (G) A+Sca-1+ cells 
differentiate towards osteoblast, positive for Osteroportin (red). (I) A+Sca-1+ cells are 
















3.3.4 Aldefluor (+) Sca-1 (+) cells are not derived from Pdx1 lineage  
The characteristics of A+Sca-1+ cells implied that they were mesenchymal cells. 
To explore the possibility that they might be of an epithelial origin, we took advantage of 
the Pdx1-cre (pancreatic and duodenal homeobox gene 1) lineage tracing mouse (Gu et al., 
2002). Pdx1 starts to express in the foregut region around Embryonic Day 8.5 (E8.5), and 
it marks the epithelia of pancreatic dorsal and ventral buds and part of the duodenal 
endoderm. In the homozygous Pdx1 null mouse, only remnants of the pancreatic buds 
remain but they fail to proliferate (Offield et al., 1996). Pdx1-cre is expressed in the 
multipotent progenitor cells in the pancreas (Gu et al., 2002).  
Pdx1-cre mice were crossed with transgenic mice carrying Rosa26-loxp-CFP-loxp-
mCherry (a kind gift from Dr. Michael Wolfgang, Johns Hopkins). Following this cross, 
the progeny would be labeled with mCherry in all the pancreatic epithelial components, 
including acinar cells, ductal cells and endocrine cells; whereas the stromal components 
would be labeled with CFP. All the A+Sca-1+ cells were labeled with CFP, indicating they 




Figure 3.4: Aldefluor (+) Sca-1 (+) cells do not come from Pdx1 lineage. 
In the Pdx1-cre; Rosa26-loxp-CFP-loxp-mCherry mouse, all the pancreatic cells of 
epithelial lineage are labeled with mCherry (red); whereas the stromal components are 
labeled with CFP (blue). A+Sca-1+ cells overlap with CFP label, indicating their 






3.3.5 Aldefluor (+) Sca-1 (+) cells are upregulated upon cerulein induced acute 
pancreatitis 
Cerulein is a decapeptide analogue (derived from Australian tree frog Litoria 
caerulea) of the pancreatic secretagogue cholecystokinin (CCK). Short-term cerulein 
administration leads to severe acute pancreatitis because of inappropriate intrapancreatic 
trypsinogen activation and subsequently, the autodigestion and death of the pancreatic cells 
(Mareninova et al., 2006). In the mouse pancreas, most exocrine cells are lost during this 
process, but in approximately 7 days following cerulein treatment, the pancreas regenerates 
almost completely (Siveke et al., 2008). Regenerating acinar cells reinstate genetic 
programs resembling those in the embryonic pancreatic precursors (Jensen et al., 2005). 
Cerulein induced pancreatitis is a widely used system to model human pancreatitis and to 
study pancreatic regeneration as well as the role of inflammation in the initiation of 
pancreatic cancer (Collins et al., 2012; Elsasser et al., 1986; Guerra et al., 2007; Jensen et 
al., 2005). 
The abundance of A+Sca-1+ cells changed during the course of pancreatic 
regeneration after the administration of cerulein (Fig. 3.5). Under normal conditions, there 
could be observed at most one A+Sca-1+ cell per acinar unit. One day after the application 
of cerulein, the population of A+Sca-1+ cells were greatly increased. Gradually, the 
number of A+Sca-1+ cells returned to the baseline level in the course of approximately 7 
days. The increase in abundance of the A+Sca-1+ cells during pancreatic injury and 
regeneration suggested that they might play a role during pancreatic remodeling, either 





Figure 3.5: The number of Aldefluor (+) Sca-1 (+) cells increases during 
cerulein induced pancreatitis. 
2 consecutive days of 6 doses of cerulein injections per day induce acute pancreatitis in 
mice. Acinar cells die but the pancreas resumes morphological and functional normality 
within 7 days.  A+Sca-1+ population is upregulated during pancreatic regeneration. In all 
the panels, A+ cells are shown in bright green. EpCam, purple. (A) Control. (B) Day 1 after 









3.3.6 Aldefluor (+) Sca-1 (+) cells contribute to exocrine and endocrine lineage ex 
vivo. 
Dissected pancreatic dorsal buds from as early as E10.5 mouse embryos can be 
cultured ex vivo (Esni et al., 2005; Gittes, 1993; Petzold and Spagnoli, 2012). Epithelium 
within the intact dorsal buds will undergo morphogenesis and cytodifferentiation to form 
both endocrine and exocrine tissue, recapitulating the endogenous developmental 
processes (Golosow and Grobstein, 1962; Miralles et al., 1998; Spooner et al., 1970). The 
ex vivo cultured embryonic mouse pancreas provide an appropriate microenvironment to 
investigate the differentiation potential of A+Sca-1+ cells isolated from adult mouse 
pancreas (Rovira et al., 2010). 
A+ cells from mT/mG mice, with global expression of membrane-tagged tdTomato 
(Muzumdar et al., 2007), were flow sorted and microinjected into dissected E12.5 dorsal 
buds (Fig. 3.6A). Interestingly, under this condition, A+ cells were able to differentiate into 
both exocrine and endocrine cells (Fig. 3.6B, B’ and C, C’). The differentiation of 
mesoderm derived population (A+ cells) into endoderm epithelial cell types (exocrine and 
endocrine cells), suggested that A+ cells could overcome their germ layer commitment 
(Grove et al., 2004). The plasticity of A+ cells makes them a potential source to, for 








Figure 3.6: Isolated Aldefluor (+) cells differentiate to endocrine and exocrine 
cells. 
(A) Experiment outline. Dorsal buds from E12.5 mouse can be dissected out. In the figure 
pancreatic buds are labeled by Pdx1 in situ hybridization to indicate the relative location. 
Flow sorted A+ cells are injected into the dorsal buds, and subsequently, the buds can be 
cultured in vitro. Cultured buds will undergo morphogenesis and cellular differentiation, 
resembling the development process in vivo. (B, B’) A+ cells (red) from an mT/mG donor 
express exocrine marker PNA (green). C-peptide (white) labels insulin secreting β-cells. 
DAPI, blue. (C, C’) A+ cells (red) from mT/mG donor express β-cell marker C-peptide 
(white). Recipient bud has Pdx1-GFP transgene. A+ cells do not have GFP expression, 
















3.3.7 Aldefluor (+) Sca-1 (+) cells secrete similar factors as embryonic mesenchyme 
As previously mentioned, A+Sca-1+ cells had long cytoplasmic processes. This 
cellular feature is a characteristic for cells forming the niche, examples of which include 
distal tip cell in C. elegans germ line (Kimble and Crittenden, 2007) and niche cells in the 
Drosophila intestine (Mathur et al., 2010). Furthermore, the fact that A+Sca-1+ cells 
resemble mesenchymal stem cells indicates that they may also secrete paracrine signals 
(Chen et al., 2008b; Gnecchi et al., 2008). To explore this possibility, we carried out a 
cytokine array analysis (RayBiotech G3) to identify cytokines secreted by A+Sca-1+ cells. 
These cells were cultured on plastic. Conditioned media from the culture were collected 
and applied onto the cytokine array, together with media secreted from E12.5 pancreatic 
mesenchyme. Embryonic mesenchymal tissue has been shown to provide signals to induce 
the proper differentiation and morphogenesis of pancreatic epithelia (Attali et al., 2007; 
Duvillie et al., 2006; Gittes et al., 1996; Jiang et al., 1999). We observed that the cytokine 
profiles of the A+Sca-1+ secretome is very similar to that of the E12.5 pancreatic 














Figure 3.7: Cytokine array  
(Meritxell Rovira). 





3.4 Discussion  
In summary, we identified a novel population of A+Sca-1+ cells in the adult mouse 
pancreas. The characteristics of these cells include: (1) they are located next to blood 
vessels and have long cytoplasmic processes; (2) they form mesenchymal spheres in vitro 
and display features of mesenchymal stem cells; (3) they originate from a non-epithelial 
lineage; (4) they are upregulated during cerulein induced acute pancreatitis; (5) they can 
be induced to differentiate into both exocrine cells and endocrine cells ex vivo and (6) they 
secrete paracrine signals. 
In the future, it would be desirable to develop a differentiation protocol in vitro and 
to characterize the functions of this A+Sca-1+ population in vivo. I showed that A+Sca-1+ 
cells were proliferative in culture and they could differentiate into an epithelial lineage 
within the pancreatic dorsal buds. Further dissection of the inductive signals from the 
embryonic buds would guide us in designing culture conditions to mimic this environment, 
and possibly to coerce these A+Sca-1+ cells towards the endocrine β-cell fate in vitro. 
Studies have shown that tissue-derived stem cells retain epigenetic memories from the cell 
of origin, thus are more likely to differentiate back into the tissue cell type of origin (Kim 
et al., 2010; Polo et al., 2010).  As a result, A+Sca-1+ cells might be more amenable to 
differentiation into β cells than both undifferentiated embryonic stem cells (ESCs) and 
induced pluripotent stem cells (iPSCs), which are mainly the two cell types currently being 
evaluated to generate new β cells (Assady et al., 2001; D'Amour et al., 2006; Kroon et al., 
2008; Zhang et al., 2009).  
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Meanwhile, the endogenous functions of A+Sca-1+ cells need to be considered. 
The mesenchymal features of these cells seem to imply that they may play a role during 
lipid deposition and stromal infiltration during pathological changes of the pancreas.  
Microarray and qRT-PCR results showed that A+Sca-1+ cells expressed high level of 
Aldh1a2, Axin2, vimentin, and GFAP (data not shown). All these markers, however, are 
expressed in other cell types inside the pancreas. Further efforts to identify a unique marker 
for A+Sca-1+ cells are warranted in order to generate a lineage tracing mouse line to study 
the in vivo function of this population. 
In addition, the fact that A+Sca-1+ cells secrete similar factors as embryonic 
mesenchyme, locate adjacent to blood vessel and display long cytoplasmic processes make 
them a likely candidate to constitute the niche microenvironment for pancreatic tissue-
resident stem cells. Further efforts to dissect the potential paracrine signaling pathway 
would presumably involve small molecule inhibitors and gene knock-out/knock-down. 
A+Sca-1+ cells may also be explored as a supporting or paracrine source for the derivation 
of new β cells. 
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Chapter 4. Dicer is required for maintenance of adult pancreatic acinar cell identity 
and plays a role in Kras-driven pancreatic neoplasia 
4.1 Introduction 
The microRNA pathway is a critical regulator of gene expression, and Dicer, an 
RNase III-containing enzyme, is a central component of the microRNA (miRNA) 
processing machinery. Deregulation of miRNAs has been implicated in a variety of 
biological process including cancer (Carthew, 2006), (Sevignani et al., 2006). In mice, 
global loss of Dicer leads to lethality before embryonic day 7.5  (Bernstein et al., 2003). 
Conditional inactivation of Dicer in numerous cell types from tissues such as the immune 
system (Cobb et al., 2005), retina  (Bernstein et al., 2003), cortex, hippocampus (Davis et 
al., 2008) and  ovary (Lei et al., 2010), has proven the essential function of Dicer in a 
number of tissue-specific contexts.   
Previous work has shown that miRNA levels fluctuate during cancer initiation and 
progression. Both tumor suppressor and oncogenic miRNAs have been described (Chang 
and Mendell, 2007; Zhang et al., 2007). In general, tumor cells display a global 
downregulation of miRNA expression (Lu et al., 2005). Recently, several reports have 
indicated that Dicer may function as a haploinsufficient tumor suppressor, as 
heterozygosity for Dicer enhances tumor development, whereas enforced Dicer 
homozygous deletion causes inhibition of tumorigenesis in certain tumor models (Kumar 
et al., 2009; Lambertz et al., 2010; Zhang et al., 2013). 
Recent publications have shown that pancreatic acinar cells display unexpected 
plasticity, and are capable of undergoing dramatic changes in differentiation in the settings 
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of both chronic pancreatitis and pancreatic cancer. Lineage tracing approaches have 
provided evidence that acinar cells in the adult pancreas have the potential to 
transdifferentiate into metaplastic ductal cells (Strobel et al., 2007). This acinar-to-ductal 
metaplasia (ADM) event precedes the formation of pancreatic intraepithelial neoplasia 
(PanIN) (Means et al., 2005; Reichert and Rustgi, 2011; Shi et al., 2013; Zhu et al., 2007). 
Acinar cells have similarly been shown to be an effective cell-of-origin for KrasG12D-
induced PanIN and pancreatic ductal adenocarcinoma (PDAC) (De La et al., 2008; Guerra 
et al., 2007; Habbe et al., 2008).  
Deletion of Dicer at the onset of pancreatic development results in defects in all 
pancreatic lineages (Lynn et al., 2007), while loss of Dicer in the pancreas at a late 
gestational stage (E18.5) results in defects in acinar cell differentiation and morphogenesis 
(Prevot et al., 2013). Interestingly, the adult pancreas seems to be extremely sensitive to 
changes in the abundance of Dicer  (Morita et al., 2009). In the Dicer hypomorphic mouse 
created by Morita et al (Morita et al., 2009), Dicer expression was reduced to 20% in all 
tissues and the only observed abnormality was in the adult pancreas.  
The motivation of the present study was to examine the role of miRNAs in normal 
pancreatic tissue homeostasis and during the initiation and progression of pancreatic 
cancer. Instead of investigating individual miRNAs, we deleted the miRNA master 
regulator Dicer in the adult exocrine pancreas with or without simultaneous activation of 
oncogenic KrasG12D. This experiment was designed to provide initial insights into the role 
of the miRNA pathway as a whole, as well as revealing the dominant mechanism of 
regulation. We found that in normal pancreata, deletion of both copies of Dicer resulted in 
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the progressive loss of differentiated acinar cells, associated with the initiation of epithelial-
to-mesenchymal transition (EMT). These changes were additionally accompanied by 
ADM and pancreatic fibrosis. In concert with KrasG12D activation, homozygous Dicer 
deletion accelerated ADM formation, but not PanIN initiation. In contrast, PanIN 
formation was enhanced in the setting of Dicer haploinsufficiency. Regardless of genotype, 
PanIN lesions were observed to have retained Dicer expression. Thus, in addition to being 
required for the maintenance of acinar cell identity, fractional changes in Dicer gene 
activity may have significant impact on the pancreatic response to oncogenic stimuli.  
Contributions: The following chapter represents the collaborative work of Dr. 
Bidyut Ghosh and myself. Dr. Bidyut Ghosh was involved in designing the experiment and 
interpreting the data. He contributed Fig. 4.5. The rest of the work was completed by 
myself.  
4.2 Materials and Methods 
4.2.1 Mouse lines 
Dicerfl/fl mice were crossed with Mist1CreERT2/+ mice (gift from Stephen F. 
Konieczny, University of Indiana). An additional lox-stop-lox Rosa26 YFP allele (hereafter 
referred to as LSL-YFP) was incorporated as a lineage marker.  The resulting Mist1CreERT2/+; 
LSL-YFP; Dicerfl/wt mice were further intercrossed or outcrossed onto a conditional LSL-
KrasG12D allele, as previously described (Habbe et al., 2008). Mice were euthanized by 
cervical dislocation under Isoflurane anesthesia. There was no surgery performed and 
animals exhibiting discomfort were euthanized. All procedures were performed under the 
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approval of the Johns Hopkins University School of Medicine Animal Care and Use 
Committee guidelines (IACUC, protocol number M012M353).  
4.2.2 Tamoxifen induced Dicer deletion 
Induction of CreERT2 activity was initiated at 8 weeks of age by administering 
5mg of tamoxifen (Sigma, 10540-29-1) for 3 consecutive days via intra-peritoneal (IP) 
injections. Control littermates were injected with corn oil alone. 
4.2.3 Pancreatic acinar isolation and in vitro culture 
Acinar units were isolated as described previously (Esni et al., 2005). Briefly, 
mouse pancreata were perfused from common bile duct with 0.375 mg/ml Collagenase-P 
(Roche, 11213857001) in Hank’s balanced salt solution (HBSS). Subsequently, pancreata 
were harvested and incubated in 37°C waterbath for 11 mins. Following multiple washes 
with HBSS, 5% FBS, the resulting acini were cultured in RPMI 1640 supplemented with 
10% fetal bovine serum (FBS) (Invitrogen), soybean trypsin inhibitor (Sigma) and 
antibiotics in low attachment 24-well plates (Corning). Acini were treated with either 
DMSO or with 4-hydroxytamoxifen (Sigma, H7904) at 20 ng/ml for 5 consecutive days to 
induce Cre-mediated deletion of Dicer in vitro.  
4.2.4 Immunohistochemistry and immunofluorescence 
Pancreata were harvested at indicated time points and were fixed in 4% 
paraformaldehyde, followed by standard paraffin or OCT embedding. Tissue was then cut 
into 5-10 µM sections. Incubations with primary antibodies were performed overnight at 
4°C using standard techniques in PBS containing 0.2% Triton and 10% FBS using the 
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following antibodies or probes: rat anti-CD49f (BD Biosciences 555734, 1:100), phalloidin 
(Invitrogen R415, 1:500), rat anti-Ecad (Invitrogen 131900, 1:200), rabbit anti-Ki67 
(Abcam Ab16667, 1:50), rabbit anti-Sox9 (Millipore ab5535, 1:200), chicken anti-
Vimentin (Millipore ab5733, 1:500), rat anti-Ncad (Abcam Ab12221, 1:200), rat anti-
EpCam (Biolegend, 118214, 1:100), rabbit anti-Amalyse (Sigma A8273, 1:500), DBA 
(Vector Labs AS2034, 1:200), rabbit anti-Dicer (Clonegene CG031, 1:1000). For 
immunohistochemistry, HRP-conjugated secondary antibodies were obtained from Vector 
Labs (MP-7401). 3-3-Diaminobenzidine tetrahydrochloride (Vector Labs) was used as a 
chromogen. Bright-field images were acquired using an Olympus BX40 light microscope. 
For immunofluorescence, secondary antibodies were obtained from Jackson 
ImmunoResearch and used at 1:300 dilution. Samples were mounted with Fluorescence 
Mounting Medium (Dako, S3023). Slides were imaged on the Nikon A1 confocal 
microscope system.  
4.3 Results 
4.3.1 Dicer knockout in mature pancreatic acinar cells 
In order to investigate the role of Dicer in the maintenance of adult acinar cell 
differentiation, we generated Mist1CreERT2; Dicerfl/fl; LSL-YFP mice (Habbe et al., 2008). 
Tamoxifen was administered to 8-week-old adult mice via intraperitoneal injection. We 
followed morphological changes in pancreata up to 6 months after tamoxifen injection (Fig. 
4.1A).  Successful Cre-mediated recombination could be visualized by the expression of 
YFP in more than 90% of the acini (Fig. 4.1B, C) and the expression of YFP was highly 
correlated with the elimination of Dicer protein, as assessed by Dicer 
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immunohistochemistry (Fig. 4.1D, E). During the time course of this study, the most 
extensive pancreatic abnormalities were observed at one month following the deletion of 
Dicer (Fig. 4.1F-K, Fig. S4.1). In some cases, pancreatic lobes were characterized by 
extreme acinar cell atrophy, with only remnants of ductal like structures left behind (Fig. 
4.1I). This was accompanied by a prominent inflammatory infiltrate (Fig. 4.1I). In the most 
severe scenario, areas of fibrosis were observed to replace the majority of normal 
pancreatic acinar tissue (Fig. S4.1A, B). By six months post-tamoxifen administration, the 
histology of pancreata resumed normality with little sign of tissue damage (Fig. 4.1K). 
Noticeably, at six months after the deletion of Dicer, regions of YFP expression became 
more sporadic (Fig. S4.1, Fig S4.2). We interpreted this increasingly patchy YFP 
expression as evidence of expanding pancreatic exocrine tissue originating from acinar 
cells that had escaped Dicer deletion. However, we cannot exclude other possibilities such 
as a transdifferentiated and/or a progenitor cell population contributing to the regenerated 
pancreata. In fact, we observed a general proliferative response even in non-acinar tissue 
after Dicer deletion (Fig.4.4B, Fig. S4.2). Notably, the histology of the pancreata from 






Figure 4.1: Deletion of Dicer alters histology in exocrine pancreas.  
(A) Experimental regimen. Tamoxifen injection was performed on 6-8 weeks old mice. (B) 
Pancreas treated with corn oil has no YFP expression. (C) Widespread Cre-mediated 
recombination is shown by YFP expression following tamoxifen induction. (D, E) 
Immunohistochemistry for Dicer on Mist-CreERT2; LSL-YFP; Dicerfl/fl mice treated with corn 
oil only (D) or those treated with tamoxifen (E). There is almost complete loss of 
cytoplasmic Dicer signal in the acinar cells in tamoxifen-treated tissue. Residual nuclear 
signal likely represents non-specific antibody labeling. (F-K) H & E staining showing the 
time-course of histologic change after tamoxifen administration. (F) Dicerfl/fl oil control. (G) 
Dicerfl/wt. Tissue is morphologically indistinguishable from oil control.  (H) Dicerfl/fl 0.5 
month after tamoxifen injection. (I) Dicerfl/fl 1 month after tamoxifen injection. Tissue 
changes are most dramatic at this time point. (J) 2 months. (K) 6 months. At this time point, 

















4.3.2 Dicer is required for the maintenance of mature acinar cell identity 
We sought to characterize changes occurring following acinar cell-specific Dicer 
deletion in additional detail. We used two markers of cell polarity, CD49f (integrin subunit 
α6) and phalloidin. CD49f forms a heterodimer with integrin β1 subunit and is present on 
the basal membrane of pancreatic acini (Bombardelli et al., 2010); while phalloidin stains 
apical actin web concentrated at the apical side of acinar cells. Using immunoflourescent 
staining, we found that these polarity markers were mislocalized in the acinar cells of the 
Dicer knockout. CD49f translocated to the lateral membrane (Fig. 4.2) and the expression 
level of CD49f was significantly increased compared with control acini. Phalloidin showed 
a diffuse pattern of staining in the Dicer-deleted animals, rather than labeling apically-







Figure 4.2: Deletion of Dicer induces loss of polarity in acinar cells following 
Dicer deletion. 
(A) Epithelial cell polarity marker CD49f (white) is expressed basally, while phalloidin 
labeling (red) is observed apically in control Mist-CreERT2; LSL-YFP; Dicerwt/wt pancreas 
following tamoxifen treatment. (B) In the Mist-CreERT2; LSL-YFP; Dicerfl/fl mice, Dicer 
deletion leads to translocation of CD49f in the lateral membrane, and loss of apical 
phalloidin labeling. Cytoplasmic expression of YFP is shown in green as a surrogate 
marker of Cre-mediated recombination. Nuclei are stained with DAPI (blue). 
 
Following Dicer deletion, pancreatic acinar cells also lost their classic rosette-like 
epithelial organization (Fig. 4.2B, Fig. 4.3B, D).  This phenotype was similar to what was 
observed by Morita et al (Morita et al., 2009) in the Dicer hypomorphic pancreas. In 
addition, acinar cells lacking Dicer developed a partial mesenchymal phenotype. This 
process of EMT was documented by decreased expression of the epithelial marker Ecad 
and EpCam and increased expression of the mesenchymal markers Vimentin and Ncad 




Figure 4.3: Adult acinar cells undergo epithelial to mesenchymal transition. 
(A) Pancreata from oil injected Mist-CreERT2; LSL-YFP; Dicerfl/fl mice do not express YFP 
(white) or vimentin (red). Ecad (green) outlines acinar cells. (B) In tamoxifen treated Mist-
CreERT2; LSL-YFP; Dicerfl/fl mice, acinar cells show co-localization of YFP and vimentin. 
Ecad expression is reduced. (C, D) Representative immunofluorescent staining for the 
mesenchymal marker Ncad (green). (C) In oil treated control pancreas, acini lack any 
Ncad expression. (D) In tamoxifen-treated Dicerfl/fl pancreas, there is membrane expression 
of Ncad. Note that there is simultaneous loss of EpCam expression (white), in Dicer 





Furthermore, in the absence of Dicer, some of the acinar cells showed evidence of 
ADM (Fig. 4.4). This was indicated by appearance of the YFP positive lineage marker in 
some of the duct-like structures, which were labeled by the lectin Dolichos Biflorus 
Agglutinin (DBA) as well as an antibody against Sox9 (Fig. 4.4, Fig. S4.1C, D). Following 
Dicer deletion, proliferative responses were observed in both acinar and nonacinar cells, 
presumably as a result of signals from pancreatic injury (Fig. 4.4A, B). An extensive 
quantification of Ki67 positive cells following tamoxifen administration revealed that 
maximum cellular proliferation occurred in the acinar cells at one month after loss of Dicer, 
with less frequent proliferation observed in other components of pancreas including ducts, 




Figure 4.4: Dicer deletion leads to upregulation of ductal markers in the acinar 
population. 
(A, B)  Pancreatic ductal marker Dolichos Biflorus Agglutinin (DBA) (purple) is 
upregulated along with cell proliferation marker Ki67 (red) in the Mist-CreERT2; Dicerfl/fl  
mice following tamoxifen injection (B) compared to control Mist-CreERT2; Dicerwt/wt  
pancreata (A). (C, D) Sox9 (red), a duct-specific transcription factor, is also upregulated in 
acinar cells and in ADM lesions in Mist-CreERT2; Dicerfl/fl  pancreata (D), while Sox9 is 
expressed only in ductal epithelial cells in control Mist-CreERT2; Dicerwt/wt  pancreata (C). 
Epithelial marker Ecad is in green and nuclei are stained with DAPI (blue). 
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In summary, we observed a major identity shift in the acinar population upon 
homozygous Dicer knockout. Acinar cells lost apical-basal polarity and transdifferentiated 
into ductal or mesenchymal cell types, suggesting that Dicer is required for the 
maintenance of acinar cell differentiation. 
4.3.3 In vitro acinar cultures confirm a cell autonomous effect of Dicer deletion 
In the Dicer knockout pancreas, an activated inflammatory response is observed 
(Fig. 4.1). Based on the fact that morphological changes in pancreatic acinar cells can be 
induced by pancreatic inflammation alone (Liou et al., 2013; Strobel et al., 2007), we 
endeavored to assess whether the phenotypes we observed after Dicer deletion in acinar 
cells were a primary effect of Dicer knockout or a secondary effect of tissue injury. For 
these studies, we utilized an in vitro acinar culture system. In this setup, the macrophages, 
neutrophils and other components of the immune system were absent. Isolated acini from 
Mist1CreERT2/+; LSL-YFP; Dicerfl/fl mice were handpicked and cultured in the presence of 
4-hydroxytamoxifen (4-OH) or DMSO control. Acini incubated with 4-OH showed down-
regulation of Ecad (Fig. 4.5A, K vs. 4.5F, P) and up-regulation of Vimentin (Fig. 4.5L vs. 
4.5Q); similar to what we observed in vivo (Fig. 4.3). Acini incubated with DMSO control 
maintained their epithelial identity (Fig. 4.5K, L, M, N, O). In these experiments, YFP 
expression following 4-OH treated acini was used as a surrogate marker for successful 
deletion of Dicer (Fig. 4.5C, H, M, R). These studies demonstrate a cell autonomous 







Figure 4.5: In vitro deletion of Dicer in pancreatic acinar cells results in initiation 
of EMT.   
(A-E) and (K-O) depict multi-channel fluorescent imaging of two representative 
pancreatic acini independently harvested from Mist1CreERT2/+;LSL-YFP; Dicerfl/fl mice and 
treated with DMSO control.  (F-J) and (P-T) depict multi-channel fluorescent imaging of 
two representative pancreatic acini isolated from Mist1CreERT2/+;LSL-YFP; Dicerfl/fl mice and 
treated with tamoxifen (TMX) to induce Cre activity. (A-J), Immunostaining of isolated 
acinus with Amylase (red), Ecad (green) and GFP (purple). There is no change in Amylase 
expression following 5 days incubation with either DMSO control (A-E) or tamoxifen 
treatment (F-J). But significant down-regulation of Ecad can be observed. (K-T), 
Immunostaining of isolated acini with Vimentin (red), Ecad (green) and YFP (purple).   
Downregulation of Ecad is accompanied by activation of vimentin in tamoxifen-treated 















4.3.4 Dicer haploinsufficiency enhances PanIN formation in an oncogene-dependent 
manner 
Loss of Dicer in normal adult pancreatic acinar tissue resulted in the initiation of 
ADM, which is a proposed precursor of PanIN (Brune et al., 2006; Reichert and Rustgi, 
2011; Shi et al., 2013). We therefore sought to determine whether loss of Dicer would 
facilitate PanIN initiation. Recent studies have shown that the Mist1CreERT2/+; LSL-KrasG12D 
mouse model fully recapitulates the initiation and progression of early human pancreatic 
neoplasia (Habbe et al., 2008). To test the function of Dicer in the context of oncogenic 
Kras-driven pancreatic neoplasia, we crossed Dicerfl/fl mice onto the Mist1CreERT2/+; LSL-
KrasG12D mice. We generated Mist1CreERT2/+; LSL-KrasG12D; Dicerfl/fl (Dicer-floxed-Kras) 
and Mist1CreERT2/+; LSL-KrasG12D; Dicerfl/+ (Dicer-het-Kras) mice, and compared them 
with Mist1CreERT2/+; LSL-KrasG12D; Dicerwt/wt (Dicer-wt-Kras) mice. Interestingly, 
immunohistochemistry for Dicer in the pancreata of Dicer-wt-Kras mice demonstrated a 
tissue-wide decrease of Dicer protein (Fig. 4.6A vs B). This observation is in line with the 
hypothesis that the global down-regulation of miRNA expression in tumors may be driven 
by alterations in the expression levels or activity of Dicer (Martello et al., 2010). Notably, 
in the same sections, PanIN lesions displayed higher levels of Dicer expression (Fig. 4.6B, 
arrows). In the Dicer-floxed-Kras mice, there was an almost complete loss of cytoplasmic 
Dicer protein in the acinar compartment, although some nuclear Dicer staining remained, 
likely representing nonspecific signal (Fig. 4.6C). Strikingly, the vast majority of 
metaplastic and neoplastic lesions preserved a moderate level of Dicer protein (Fig. 4.6D), 
suggesting selective pressure to retain at least some level of Dicer expression during the 
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initiation of pancreatic neoplasia. This is consistent with recent work showing certain types 
of tumors select against full loss of Dicer function (Kumar et al., 2009). 
We quantified the pancreatic phenotypic abnormalities, including ADM and PanIN, 
in both the Dicer-floxed-Kras and Dicer-het-Kras mice. We observed that Dicer-het-Kras 
mice developed PanINs at earlier time points and at much higher frequency than the Dicer-
floxed-Kras mice and the Dicer-wt-Kras mice in the same cohort (Fig. 4.6E-H). At the two-
month time point, Dicer-het-Kras mice had PanIN comprising approximately 4% of total 
pancreatic surface area, compared to the 0.8% in Dicer-floxed–Kras mice and 1% in Dicer-
wt–Kras mice (Fig. 4.6H). In contrast, Dicer-floxed-Kras mice have an increase in ADM 
compared with Dicer-het-Kras and Dicer-wt-Kras pancreata. (Fig. 4.6H). This is consistent 
with our previous assumption, indicating that Dicer loss accelerates the formation of ADM 
under conditions of Kras activation, but in the absence of Dicer these ADM lesions are 









Figure 4.6: Kras-driven pancreatic lesions are sensitive to Dicer gene dosage. 
(A-D) Brown staining indicates immunohistochemical labeling for Dicer (hemotoxylin 
counterstain, blue). (A) Wildtype pancreas. There is strong cytoplasmic labeling for Dicer 
in acinar cells. (B) Dicer-wt-Kras. Dicer is downregulated in acinar cells following 
oncogenic Kras activation. Notice that PanIN lesions (arrows) have higher Dicer 
expression. (C) Dicer-floxed-Kras. Residual nuclear signals likely represent non-specific 
antibody labeling. (D) In the Dicer-floxed-Kras pancreata, areas of ADM retain higher levels 
Dicer expression. Normal ductal epithelium, stromal cells and endocrine cells (lower 
right) also show normal expression of Dicer. E-G, H&E labeling demonstrates 
representative histology (E) Dicer-wt-Kras, (F) Dicer-het-Kras and (G) Dicer-floxed-Kras 
pancreata. (H) Quantification of surface area occupied by stromal infiltrate, ADM and 
















Dicer is a master regulator of the miRNA pathway. The deletion of Dicer leads to 
loss of mature miRNAs (Chen et al., 2008a; Murchison et al., 2005). To assess the 
requirement of miRNAs in adult acinar tissue, we combined a floxed Dicer allele with an 
exocrine pancreas specific, tamoxifen-inducible Cre driver, Mist1CreERT2 (Habbe et al., 
2008). In this report we show that Dicer is essential for the maintenance of normal acinar 
cell identity, with homozygous Dicer deletion resulting in loss of acinar cell polarity, and 
the induction of both ADM and EMT.  When combined with activation of oncogenic Kras, 
homozygous Dicer deletion leads to accelerated ADM formation but no change in the rate 
of PanIN initiation or progression. We also present evidence that PanIN lesions select 
against complete loss of Dicer, and that Dicer haploinsufficiency accelerates PanIN 
initiation.  
In non-neoplastic pancreas, histologic changes associated with conditional Dicer 
deletion were manifested within 72 hours following tamoxifen injection (data not shown). 
These cellular responses included loss of cell polarity and the induction of EMT and ADM, 
indicating an overall increase in cellular plasticity. In vitro induction of Dicer deletion in 
isolated pancreatic acini confirmed that these changes represented a cell autonomous effect 
of Dicer loss. In the in vivo setting, we did observe a robust inflammatory response after 
Dicer deletion (Fig. 4.1). In fact, some of the hyperplastic ductal-like structure we observed 
were not of apparent acinar cell origin, based on the absence of a heritable lineage marker 
(Fig. S4.1). While we cannot entirely rule out the possibility that the absence of lineage 
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marker expression is due to mosaic Cre activity, these structures may have arisen from 
ductal or other cell populations as a non-cell autonomous response to acinar cell injury. 
In the absence of Kras activation, acinar cells eventually regenerated following 
widespread Dicer deletion. The source of newly generated acinar cells may similarly 
involve either proliferation of preexisting acinar cells that escaped Dicer deletion (Desai et 
al., 2007; Strobel et al., 2007), or from the expansion of a transdifferentiated/progenitor 
cell population such as ductal cells (Criscimanna et al., 2011).  
When accompanied by Kras activation, ADM lesions persisted and progressed. 
Based on immunohistochemical labeling, these ADM and PanIN lesions seemed to select 
against complete loss of Dicer. This observation is in line with multiple cancer models in 
which enforced Dicer deletion cause inhibition of tumorigenesis, and tumors from Dicerfl/fl 
animals typically maintain one functional Dicer allele (Kumar et al., 2009; Lambertz et al., 
2010; Yoshikawa et al., 2013; Zhang et al., 2013). One potential limitation of our study is 
that both the floxed Dicer alleles and LSL-KrasG12D allele were recombined simultaneously 
in response to tamoxifen administration. One possibility is that during different stages of 
pancreatic tumor initiation and progression, there are divergent requirements for different 
levels of Dicer activity. Further studies that temporally separate the Dicer deletion and 
Kras activation events, as might be achieved using a tetracycline-regulated system (Furth 
et al., 1994; Saborowski et al., 2014), are needed to further investigate time- and tumor 
stage-dependent influences of Dicer.  
A recent similar study by Morris et al was published  describing the role of Dicer 
in the regulation of Kras-mediated ADM and PanIN (Morris et al., 2014). This study 
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reported that loss of Dicer compromised acinar identity and promoted Kras-driven ADM. 
At the same time, Dicer loss did not accelerate PanIN or PDAC development. Overall, 
their findings are comparable to our results. The major differences between the Morris 
paper and the current study involve the use of different Cre driver lines.  In the study of 
Morris and colleagues, a Pdx1:cre line was utilized in which Cre activity is initiated in 
multi-lineage embryonic pancreatic progenitors at E12 (Heiser et al., 2006). In their setting, 
Dicer is conditionally deleted in all pancreatic epithelial lineages, while in our study, we 
have interrogated the function of Dicer specifically in adult acinar cells. Using this 
approach, we demonstrate that Dicer loss restricted to adult acinar cells is sufficient to 
induce an ADM reprogramming process, as characterized by the induction of DBA and 
Sox9 expression. A recent study demonstrated that the upregulation of Sox9 in the acinar 
population is an early tumor-initiating event (Kopp et al., 2012). Thus, miRNA 
deregulation in the acinar compartment may induce an early cellular change that renders 
acinar cells more prone to additional oncogenic stimuli, including Kras activation (Fig. 
4.7). 
One confounding factor in the current study is that there are different categories of 
miRNAs, some of them tumor suppressors, some of them oncogenes (Zhang et al., 2007). 
Yet Dicer knockout will impair the entire miRNA biogenesis pathway. In the future, we 
would like to pinpoint the role of individual miRNAs in pancreatic cancer initiation and 
progression. A good candidate is miR-217 (Zhao et al., 2010). In the next chapter, I would 
like to present our initial effort to employ zebrafish as a model to study pancreatic cancer 




In conclusion, we have established that Dicer is essential for the maintenance of 
acinar cell identity in the adult post-differentiated exocrine pancreas. Different levels of 
Dicer may be required at different stages of Kras-driven pancreatic tumorigenesis. Further 
work is needed to examine the functions of individual microRNAs and the time-dependent 
role of Dicer during pancreatic cancer initiation and progression.   
 
Figure 4.7: Summary of fate changes of acinar cells. 
Temporary loss of Dicer induces cellular changes in the acinar population. These changes 
include loss of polarity, EMT and ADM. Acinar cells start to express ductal cell signature 
such as Sox9. Eventually, the pancreas regenerates. With the activation of oncogenic Kras, 
the injury persists in the acinar cells. This may eventually lead to cellular transformation 











Figure S4.1: Dicer deletion leads to pancreatic fibrosis. 
(A-B) Trichrome staining shows fibrosis in the pancreas of 1 month post tamoxifen 
treatment. (A) Oil control. (B) 1 month post tamoxifen. There is severe phenotype with 
partial loss of acinar mass and sclerotic tissue. (C) 6 months after tamoxifen 
administration, YFP expression (green) becomes patchy. Some of the acinar units resemble 
ductal like structures as shown by Ecad (white) staining. Arrow points to one ductal like 
structure that is positive for YFP. Arrowheads point to several ductal like structures that 
are negative for YFP. (D) Progression of histologic changes following tamoxifen treatment. 
The most extensive changes are evident at one month post-tamoxifen. By 6 months, the 








Figure S4.2: Tissue-wide proliferation response after Dicer deletion. 
Ki67 (red) labels proliferating cells in pancreata (A) 75h, (B) 2 weeks, (C) 1 months, (D) 2 
months, (E) 6 months post tamoxifen administration. In (A) Ecad is shown in green, DBA 
in white and DAPI in blue. In B-E, YFP (green) labels cell lineages in which Cre-mediated 
recombination has occurred.  Note relative expansion of YFP-negative regions at 2 months 
and 6 months post-tamoxifen. Sections are co-stained with DBA (white) and DAPI (blue). 



















Chapter 5. TALEN targeting the zebrafish mir-216b-217 miRNA cluster 
5.1 Introduction 
The zebrafish has evolved as an excellent model for cancer studying. It develops 
cancers that are histologically and genetically similar to human cancers. The ability to carry 
out in vivo live imaging, tumor transplantation, large-scale chemical and genetic screens, 
transgenesis, and with the advance of transcription activator-like effector nucleases 
(TALENs) and clustered regularly interspaced short palindromic repeat (CRISPRs), 
targeted knock-in and knock-out in zebrafish, offers a unique opportunity to study cancer 
biology and to functionally annotate the cancer genome in the post-genomic era (Feitsma 
and Cuppen, 2008; Liu and Leach, 2011b; White et al., 2013).  
Pancreatic cancer is one of the most deadly cancers (American-Cancer-Society, 
2014). Although progress has been made during the past few decades in the clinical 
management of pancreatic cancer patients, the 5 year survival rate for this cancer is still as 
low as 5% (American-Cancer-Society, 2014). Currently, the first line therapies for 
pancreatic cancer treatment are two chemotherapeutic agents, 5-fluorouracil and 
gemcitabine (Berlin et al., 2002; Burris et al., 1997; Neoptolemos et al., 2004). However, 
both of these drugs target DNA replicating events and thus are not cancer cell-type specific 
(Costello et al., 2012). It would be ideal if we can design an in vivo high throughput strategy 
to screen for potential drugs that specifically eliminate pancreatic cancer cells (Suggitt and 
Bibby, 2005). The other problem of pancreatic cancer is that there are few symptoms 
during its early stages. The majority of pancreatic patients present clinically with late stage 
metastatic cancer that is not surgically resectable (Li et al., 2004). Consequently, it is highly 
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relevant to generate animal models, either by transgenesis or xenograft, to better 
understand the pancreatic cancer biology and to discover early diagnostic markers 
(Hingorani et al., 2003; Kim et al., 2009a).  
In our laboratory, we have been focusing on developing a zebrafish pancreatic 
cancer model. Our knowledge and experience from genetically engineered mouse models 
guides us in constructing zebrafish pancreatic cancer models. In human pancreatic cancer 
patients, the most frequently observed genetic alteration is activating mutation of Kras 
(Hruban et al., 1993; Jones et al., 2008). In parallel, the two most widely used mouse 
models for pancreatic cancer overexpress oncogenic Kras in a pancreatic specific manner. 
These two models are Pdx1-Cre;LSL-KrasG12D and Ptf1a-Cre;LSL-KrasG12D  (Grippo and 
Tuveson, 2010; Herreros-Villanueva et al., 2012; Leach, 2004). Transgenic mice develop 
pancreatic lesions consistently and the cancer morphologies closely mimic the human 
counterparts (Hingorani et al., 2003). In our previous work, we established two zebrafish 
lines expressing oncogenic Kras (Liu and Leach, 2011a; Park et al., 2008b). In the first 
model, we modified a 160 kb BAC spanning the zebrafish ptf1a locus. The coding 
sequence of ptf1a was replaced with the human KrasG12V  cDNA (Park et al., 2008b). By 
nine months of age, the majority of transgenic fish developed discernible tumors. However, 
the fish carried predominantly acinar cell carcinomas as opposed to the most frequently 
observed duct-like structures in the human PDAC (Park et al., 2008b). Our second model 
utilized the Gal4/UAS system to express the human KrasG12V in the exocrine pancreas (Liu 
and Leach, 2011a). Specifically, transgenic fish was created carrying 
ptf1a:Gal4;UAS:eGFP-hKrasG12V. However, this model also induced predominantly 
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acinar cell carcinomas with a few tumors containing mixed acinar and ductal differentiation 
(Liu and Leach, 2011a).  
Using the newly generated ptf1a:creERT2 driver line (Chapter 2), we established a 
third transgenic fish line: ptf1a:creERT2;ubi:loxp-CFP-loxp-Gal4;UAS:eGFP-hKrasG12D. 
For the first time, we recovered fish that had developed PanINs histologically resembling 
human pancreatic lesions. Zebrafish PanINs were observed in 68.7% of the total pancreatic 
area and contained the spectrum of all histological grades (Joon Park, personal 
communication). Moreover, TALENs and CRISPRs made it feasible to carry out further 
targeted mutagenesis of potential tumor suppressors and oncogenes. Finally, we are 
equipped with all the right tools to functionally annotate the pancreatic cancer genome.  
miR-217 is among the first candidates we set out to evaluate in the context of 
pancreatic cancer. It has been shown to function both as a tumor suppressor and an 
oncogene in different systems (de Yebenes et al., 2014; Kato et al., 2009; Su et al., 2014; 
Zhao et al., 2010). miR-217 is located within a miRNA cluster in the genome: mir-216b-
217. This cluster has three miRNAs: miR-216b, miR-216a and miR-217. We targeted the 
zebrafish mir-216b-217 cluster using TALEN mutagenesis. We established independent 
founder fish lines carrying mutations for: (1) mir-216a and mir-216b; (2) mir-217; and, (3) 
deletions of the whole mir-216b-217 cluster. Homozygous mutant fish were hatched 
following Mendelian ratios; they were morphologically indistinguishable from wildtype 
controls. To evaluate the role of these miRNAs in pancreatic cancer, further crossing is in 
progress between these miRNA mutant lines and the ptf1a:creERT2;ubi:loxp-CFP-loxp-
Gal4;UAS:eGFP-hKrasG12D line. Once we obtain fish with desired genotypes, we will 
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dissect out the fish pancreata at different time point following 4-Hydroxytamoxifen (4-
OHT) injection and compare the cancer incidences as well as histological grades between 
miRNA knockout fish and miRNA wildtype fish.  
Contributions: The following chapter represents the collaborative work of Dr. Joon 
Park and myself. Dr. Joon Park established the zebrafish pancreatic cancer model. He 
contributed Fig. 5.1. The rest of the work was fulfilled by myself.  
5.2 Materials and Methods 
5.2.1 TALEN mutagenesis 
Please refer to Addgene Golden Gate TALEN assembly protocol, which is an 
expanded and slightly modified TAL assembly protocol published originally by Cermak, 
et al., Efficient design and assembly of custom TALEN and other TAL effector-based 
constructs for DNA targeting, Nucleic Acids Research, 2011, 39 (12) (Cermak et al., 2011). 
The final destination vector used in our study is from David Grunwald lab: 
pCS2TAL3-DD and pCS2TALE3-RR (Dahlem et al., 2012) with restriction sites BamH1 
and Sph1 flanking the inserts.  
Correctly assembled pCS2TAL3-DD and pCS2TAL3-RR TALEN plasmids were 
linearized with Not1 and used as templates to generate 5′-capped mRNA by in vitro 
transcription (mMESSAGE mMACHINE SP6 kit, Life technologies, AM1340). About 
150 pg of each mRNA was injected into the cytoplasm of 1 cell stage zebrafish embryos. 
5.2.2 High-resolution melt analysis (HRMA) 
HRMA was employed to assess the efficiency of TALEN-induced mutations in the 
injected F0 generation, or in the screening of germline transmission. HRMA was 
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performed according to manufacturer’s instruction (Bio-Rad). Briefly, primers were 
designed to amplify an 85–125 bp amplicon that flanking the genomic target site. Care was 
taken in the designing of TALEN target sites so that the entire region was not polymorphic 
in the wildtype zebrafish. Precision melt supermix (Bio-Rad, 172-5110) was used to set up 
the following reaction: 
 
Component Volume per 10 µl reaction, µl 
Precision Melt supermix 5 
2 µM (each) primer mix 1 
DNase-free water -- 
Genomic DNA 4 
Total reaction mix volume 10 
 
Amplification condition was: denaturation at 95 oC, 2 min; 42 cycles of 95 oC, 10 
s; 58 oC (or other primer-specific annealing temperature), 30 s; 72 oC, 30 s. Melt curve was 
performed according the following procedure: denaturation at 95 oC, 30 s; 60 oC, 1 min; 
65-95 oC (in 0.2 oC increments), 10 s/step.  
Reaction was carried out on a CFX96 Touch™ Real-Time PCR Detection System 
(Bio-Rad). Data were analyzed using Precision Melt AnalysisTM software.  
An example of HRMA result is shown below. Zebrafish embryos 2 days post 
TALEN injection were collected and pooled into groups of 5. These samples were 
subsequently incubated with 50 µl of DNA extraction solution prepared fresh (10 mM Tris, 
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pH 8.0, 10 mM EDTA, 200 µg/ml Proteinase K) for 3 hours at 50 oC. After 95 oC for 10 
mins of heat inactivation, resulting DNAs were added directly to the HRMA reaction. 
HRM graph shows that the profiles from uninjected wildtype embryos clustered together. 
The TALEN injected embryos all clustered differently compared with wildtype, indicating 
the successful creation of indels.  
 
 
5.2.3 Allele-specific PCR for genotyping 
For offspring of established F1 generation, their genotypes were identified 









































5.2.4 Generation of transgenic zebrafish 
All experiments involving zebrafish were approved by the Johns Hopkins 
University Institutional Animal Care and Use Committee. Fish were raised and maintained 
under standard laboratory conditions. The following strains were established and/or 
utilized: ptf1a:creERT2;ubi:loxP-eCFP-loxP-nuclear-mCherry, ptf1a:creERT2;ubi:lox-
nuclear-eCFP-lox-Gal4-VP16;UAS:eGFP-KRASG12D. Larvae were anaesthetized in 0.16% 
tricaine (3-aminobenzoic acid ethylester, A-5040, Sigma, pH 7.0). Adult zebrafish were 
euthanized by induction of tricaine anesthesia followed by placement in an ice bath, 
consistent with recommendations of the Panel on Euthanasia of the American Veterinary 
Association. 
5.3 Results 
5.3.1 Development of PanIN in the ptf1a:creERT2;ubi:lox-nuclear-eCFP-lox-
Gal4;UAS:eGFP-KrasG12D fish  
The previous two fish lines we created were ptf1a:KrasG12V and 
ptf1a:Gal4;UAS:eGFP-hKrasG12V (Liu and Leach, 2011a; Liu and Leach, 2011b; Park et 
al., 2008a). In terms of modeling pancreatic ductal adenocarcinoma (PDAC), the dominant 
form of human pancreatic cancer (Hezel et al., 2006), both of these lines have problems 
because they give rise to predominantly acinar cell carcinoma. We reasoned that the 
obstacle could have been the dependency of the expression of the oncogenic Kras on the 
ptf1a promoter, as ptf1a expression is restricted to acinar cells in the adult mature pancreas. 
Acinar ductal metaplastic transdifferentiation during pancreatic tumorigenesis may down-
regulate the expression of ptf1a and subsequently compromise the expression of Kras. Thus 
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dysplastic acinar cells are selected against and tumor cells maintain their acinar identify 
(Means et al., 2005; Rodolosse et al., 2004). Coincidently, the mouse pancreatic cancer 
model, where Ptf1a:cre drives the oncogenic Kras expression, is in effect heterozygous for 
Ptf1a, due to the fact that the Ptf1a:cre allele in mouse is a knockin allele and the 
endogenous expression of Ptf1a from the same locus is prevented (Hingorani et al., 2003).  
Insights that we acquired from zebrafish ptf1a lineage tracing studies (Chapter 2) indicate 
that acinar cells with reduced ptf1a dosage have more plasticity. Consequently, 
haploinsufficiency in the mouse model of pancreatic cancer may be compatible with the 
observed ductal metaplasia.  
To release Kras from complete ptf1a-dependency, we designed a third zebrafish 
pancreatic cancer model: ptf1a:creERT2;ubi:lox-nuclear-eCFP-lox-Gal4;UAS:eGFP-
KrasG12D (Fig. 5.1). The bipartite Gal4/UAS transgenic expression system was first 
developed in Drosophila and has since been adapted to zebrafish (Duffy, 2002; Halpern et 
al., 2008). In the activator line the transcriptional activator Gal4 is placed under the control 
of a specific promoter, while in the effector line the gene of interest is fused to the upstream 
activating sequences (UAS), which contains the DNA-binding motif of Gal4 (Scheer and 
Campos-Ortega, 1999). This system shows great sensitivity and strong signal amplification 
capability (Asakawa and Kawakami, 2008; Halpern et al., 2008). In our model, the 
expression of Gal4 is initially dependent on the ptf1a promoter activity, but subsequently 
the ubiquitin promoter will drive the continuous expression of Gal4 even if ptf1a levels are 
reduced. We were gratified to observe, for the first time, PanIN lesions in transgenic fish 






Figure 5.1: zebrafish pancreatic cancer model  
(unpublished data from Dr. Joon Park). 
(A) The transgenic system we developed to induce zebrafish pancreatic cancer. (B) 24 
weeks after 4-OHT injection, the gut bulb was dissected out. A tumor mass is discernable 
by eGFP fluorescence. (C) H&E from control fish. (D) H&E from transgenic fish 24 weeks 








5.3.2 The mir-216b-217 miRNA cluster 
Having developed a zebrafish model of pancreatic cancer that recapitulates the 
human pathology, we proceeded to employ this system to test oncogenic/tumor suppressor 
activities of different genes and genomic elements.  
One interesting candidate is miR-217. miR-217 has been shown to function as a 
tumor suppressor and targets Kras in pancreatic cancer (Zhao et al., 2010). Overexpression 
of miR-217 inhibits the anchorage-independent growth of pancreatic cancer cell lines and 
reduces tumor load in a xenograft model (Zhao et al., 2010). In human, miR-217 is down 
regulated in PDAC and PanIN but not in pancreatitis, establishing it as a potential 
biomarker in diagnostic procedures (Ali et al., 2012; Schultz et al., 2012; Szafranska et al., 
2007; Xue et al., 2013; Zhao et al., 2010).  
In the zebrafish genome, miR-217 is located in a cluster along with miR-216a and 
miR-216b within a 600 bp section on chromosome 22 (Fig. 5.2A). Individual miRNAs in 
the cluster are among the most evolutionarily conserved miRNAs (Kiezun et al., 2012). In 
addition, the cluster configuration is preserved. In the zebrafish, all three miRNAs seem to 
be transcribed from one polycistron (Fig. 5.2A’, A’’). They are expressed specifically in 





Figure 5.2: mir-216b-217 genomic locus and expression pattern.  
(A)  UCSC genome browser screen-shot shows the relative location of the three miRNAs. 
They are located on the reverse strand of Chr.22. A’, locations of primers used in RT-PCR 
reaction. For clarity, the mir-216b-217 cluster is shown with the transcription starting site 
on the left. A’’, agarose gel showing products from RT-PCR reaction. Primers used in the 
reaction are indicated at the bottom of the gel. Templates are listed on the right. The faint 
band in lane 1 with mir-216b_F + mir-217_R primer pair indicates that the whole cluster 
is co-transcribed. (B-G) LNA in situ hybridizations of miRNAs. (B-E) Sections from 5 dpf 
fish. (F-G) Section from adult fish. In situ hybridization was developed using NBP/BCIP 
reagents and signals are purple-blue. All the miRNAs have acinar specific expression. 





5.3.3 Targeting the mir-216b-217 miRNA cluster using TALEN 
We made use of the powerful Transcription activator-like (TAL) effector nucleases 
(TALENs) system to create mutations in the mir-216b-217 microRNA cluster. TALENs 
have been used to introduce locus-specific double-stranded breaks as well as homology-
derived repairs with little off-target effects in zebrafish (Bedell et al., 2012; Dahlem et al., 
2012). We designed 3 pairs of TALENs targeting mir-216a, mir-216b and mir-217 
individually. Taking into consideration of the potential functional redundancy of miRNAs 
within the same miRNA family (Brennecke et al., 2005), we decided to mutate mir-216a 
and mir-216b simultaneously, aiming for bi-locus mutagenesis. Furthermore, all the 
miRNAs within the miRNA cluster may have similar biological functions (Kim et al., 
2009b). As a result, a deletion mutation encompassing the entire region is desirable to 
reveal the function of the miRNA cluster.  The above mentioned schemes can be easily 
achieved by injecting zebrafish embryos with multiplexed TALEN pairs targeting various 
loci. We observed that, when injected individually, each TALEN pair achieved 100% 
efficiency in introducing targeted small indel mutations (assessed by HRMA). By 
comparison, when two pairs of TALENs were co-injected, the efficiency dropped. 
Approximately 50% of the resulting fish carried mutations in at least one loci. Furthermore, 
when two TALEN pairs are within short distance apart, instead of recovering mutants 
carrying deletions spanning the entire region, we obtained fish carrying small indels for 
each locus (Fig. 5.3A). However, when TALEN targets are located further apart, mutants 
with big deletions were obtained (Fig. 5.3C). Figure 5.3 summarizes the founder lines we 
created carrying mutations for different miRNAs. In summary, TALEN technology 
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facilitates targeting of multiple genomic regions simultaneously that may be challenging 
or time consuming to target by traditional methods.  By co-injection of multiple TALEN 










Figure 5.3: Establishing F1 founders carrying mutations in the mir-216b-217 
miRNA cluster. 
(A) Sequences of the founder lines carrying mutations in mir-216a and mir-216b region. 
(B) Sequences of the founder lines carrying mutations in mir-217 region. (C) Sequences of 
the founder lines carrying mutations in mir-216b-217 cluster. Notice that M1 founder fish 
has small indels in mir-216b and mir-217 independently, instead of carrying deletion of 
the whole cluster. In all the sequences, blue nucleotides indicate the TALEN target sites. 
Short hairpin structures of pre-miRNAs are shown above each individual sequences. 
Underlined nucleotides are part of the mature miRNAs. (D-G) miR-216a in situ 
hybridization on (D, F) d6 wt fish pancreata, or, (E, G) d6 mir-216b-217 homozygous 
mutant pancreata. (D, E) and (F, G) are two independent experiments. Hybridization 

















5.3.4 Homozygous mutant fish of mir-216a/b, mir-217 and the mir-216b-217 miRNA 
cluster do not show developmental defects  
We crossed heterozygous F1 founder fish with reporter fish lines carrying 
transgenes ptf1a:GFP, ins:mCherry and/or Tp1:hmgb1-mCherry (THM) to label acinar 
cells, endocrine β cells and Notch-responsive cells, respectively. Resulting fish were 
intercrossed to derive fish homozygous for each mutation. At 6dpf, we dissected out the 
pancreata and checked for marker expressions. Homozygous mutant fish of mir-216a/b, 
mir-217 or mir-216b-217 were hatched according to Mendelian ratios and did not manifest 




Figure 5.4: Homozygous mutant fish for each miRNAs do not display 
developmental defects. 
Exocrine pancreas is labeled by the ptf1a:GFP transgenic marker. Endocrine components 
are indicated by ins:mCherry transgene or by immunofluorescent staining for Insulin 
(Ins), Glucagon (Gluc), Somatostatin (Sst). Pancreatic Notch-responsive cells are labeled 




5.3.5 The role of mir-216a, mir-216b and mir-217 in pancreatic cancer initiation and 
progression 
Having generated the corresponding mutations, we now propose to make use of 
the newly generated zebrafish pancreatic cancer system to address the role of these 
miRNAs in pancreatic cancer initiation and progression. Fig. 5.5 shows our crossing 
scheme to generate fish with all the transgenic and mutation components. 
 
Figure 5.5: Crossing scheme. 
The current experimentation represents our initial effort to assess the pipeline to 
functionally annotate the pancreatic cancer genome in zebrafish. Once the system is set up, 
we will move on to create more zebrafish mutant lines carrying orthologs of mutations 
having been discovered in human pancreatic cancer. Especially, the large-scale targeted 
genome-editing approaches made available by TALEN and CRISPR technologies broaden 





In summary, we created a zebrafish pancreatic cancer model that recapitulates the 
human pancreatic cancer histology. Using the newly developed exciting TALEN 
technique, we created zebrafish carrying mutations of potential tumor suppressors. No 
apparent developmental defects were observed in homozygous mutant fish. Currently, 
crosses of different transgenic fish are on-going in order to generate the fish with desired 
genetypes. They are: mir-216a/bmut/mut;ptf1a:creERT2;lox-eCFP-lox-Gal4;UAS:KrasG12D, 
mir-217mut/mut;ptf1a:creERT2;lox-CFP-lox-Gal4;UAS:KrasG12D, and mir-216b-
217mut/mut;ptf1a:creERT2;lox-CFP-lox-Gal4;UAS:KrasG12D. We are in the final stage of 
developing an in vivo testing pipeline to functionally annotate the pancreatic cancer 
genome.  
There are still some potential caveats of the system that still need to be addressed. 
First of all, the penetrance of pancreatic cancer is low in our ptf1a:creERT2;ubi:lox-CFP-
lox-Gal4;UAS:eGFP-KrasG12D model. Preliminary data showed that around 11% of the 
fish carrying all the genetic components would develop PanIN and pancreatic tumor (Dr. 
Joon Park, personal communication). The reason of the low penetrance is likely to be the 
reduced efficiency of ptf1a:creERT2 activity in the adult fish. For those fish in which we 
did not observe tumor mass, eGFP activity was not detected as well. Furthermore, in the 
ptf1a:creERT2; ubi:loxp-CFP-loxp-nuclear-mCherry control fish, adult fish have similarly 
low Cre activity. We will need to screen for the best fish line that exhibits high inducible 
Cre activity in adult and expand them so as to reduce the variability of results among 
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different fish. Second, the average time it takes to develop PanIN lesions in zebrafish is 
more than 24 weeks; whereas in the mouse model of pancreatic cancer, lesions with similar 
histological grade starts to appear  as early as 3 weeks. We can potentially shorten the time 
course of cancer development in zebrafish by cerulein injection to induce pancreatitis 
(Carriere et al., 2009; Guerra et al., 2007), or alternatively, by increasing the copy number 
of the UAS:eGFP-KrasG12D transgene through plasmid injection. Park et al. recently 
showed that injection of UAS:eGFP-KrasG12D plasmid into ptf1a:Gal4 fish can induce 









Chapter 6. Conclusions 
6.1 Research summaries 
In summary, during my Ph.D. training, I explored different aspects of the pancreatic 
biology.  
In Chapter 2, I described the lineage analysis of the ptf1a-expressing cells during 
zebrafish development. I demonstrated that there are a small number of ptf1a-expressing 
cells giving rise to pancreatic Notch-responsive-cells (PNCs) and endocrine cells during 
development. The ptf1a lineage to some degree contributes to the regeneration of β cells. 
In the ptf1a heterozygous mutant fish, a higher proportion of ptf1a lineage-labeled cells are 
traced into PNCs and endocrine compartment. Further reduction of ptf1a dosage converts 
the ventrally derived pancreatic progenitor cells to gall bladder and other nonpancreatic 
cell fate.  
In Chapter 3, I presented the characterization of a potential progenitor population, 
A+Sca-1+ cells, in the adult mouse pancreas. A+Sca-1+ cells have mesenchymal stem cell 
features. They have the capacity to be differentiated into both endocrine and exocrine cells 
in the dorsal bud ex vivo culture system. Furthermore, this population of cells secrete 
signaling molecules that highly resemble those secreted by embryonic mesenchyme.  
In Chapter 4, I showed the work we performed on deciphering the role of Dicer in 
the mature acinar cells during normal tissue homeostasis and pancreatic cancer initiation. 
We found that Dicer is essential for the maintenance of acinar cell identity. Acinar cells 
lacking Dicer showed increased plasticity, as evidenced by loss of polarity, initiation of 
epithelial-to-mesenchymal transition (EMT) and acinar-to-ductal metaplasia (ADM). In 
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the context of oncogenic Kras activation, the initiation of ADM and pancreatic 
intraepithelial neoplasia (PanIN) were both highly sensitive to Dicer gene dosage. 
Homozygous Dicer deletion accelerated the formation of ADM but not PanIN. In contrast, 
heterozygous Dicer deletion accelerated PanIN initiation, revealing complex roles for 
Dicer in the regulation of both normal and neoplastic pancreatic epithelial identity. 
Finally, in Chapter 5, I outlined our effort to establish the zebrafish model of 
pancreatic cancer and our initial attempt to annotate the pancreatic cancer genome in vivo 
by functional genomic approaches as typified by TALEN mutagenesis.  
The different parts of my thesis work are interconnected. In general, adult tissue-
resident stem cells are believed to be allocated during early development (Barker et al., 
2010). These somatic stem cells maintain tissue function by replacing terminally 
differentiated, aged or damaged cells (Mimeault and Batra, 2008). It is widely thought that 
cancers originate from these preexisting stem cells and the tumorigenesis process 
“borrows” the developmental programs and “hijacks” physiological homeostasis 
mechanisms (Lobo et al., 2007; Reya et al., 2001). By studying the entire process, from 
development to adult stem cells to cancer, we can gain extensive knowledge of the 
regulatory pathways of normal biological system as well as cancer ontogeny. 
One common theme emerged from my studies is the plasticity of pancreatic cells. 
Example 1: During development, I showed that cells with reduced dosages of ptf1a are 
more inclined to differentiate into pancreatic PNCs and endocrine cells. Example 2: In the 
adult pancreas, I identified an A+Sca-1+ population that can be differentiated into multiple 
mesenchymal lineages in vitro and endocrine/exocrine cell fate in dorsal buds explant ex 
 
128 
vivo. Example 3: Adult pancreatic acinar cells undergo epithelial mesenchymal transition 
and acinar ductal metaplasia upon Dicer deletion. The cellular plasticity is a double-edged 
sword. On one hand, the ease of cell fate conversion makes it conceivable to design a 
strategy to convert different cell types in the pancreas into insulin-secreting β cells. Both 
type 1 and type 2 diabetes patients suffer from β-cell deficiency. They will both benefit 
from the increase of β-cell numbers. On the other hand, the transdifferentiation of acinar 
cells may be the underlying mechanism of pancreatic neoplastic transformation. 
Theoretically, if we devise a way to maintain the acinar cell fate or reverse the cell-fate 
conversion process, we may be able to improve treatment of pancreatic cancer patients.  
The other valuable insight we gained from my thesis work is that there are striking 
similarities in the regulatory mechanisms between mouse and zebrafish. Our observations, 
together with accumulated knowledge, show that: the pancreas derives from dorsal and 
ventral anlagen in both species; Ptf1a is one of the earliest transcription factors expressed 
in the pancreatic field; reduced dosage of Ptf1a is correlated with greater lineage 
differentiation potentials; progenitor cells with severe reduction of Ptf1a levels transfated 
into gall bladder or other cell types. Furthermore, oncogenic Kras mediates pancreatic 
tumorigenesis stemming from the acinar population in both mouse and zebrafish.  
Traditionally, mouse has been the favorite model of modern genetics due to the 
availability of embryonic stem cells, homologous recombination and other genetic 
engineering technologies. For zebrafish, although there are strategies such as random 
mutagenesis using ENU, retroviruses or transposons, the ability to engineer specific 
mutations has remained elusive. However, the latest introduction of TALEN and CRISPR 
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methods for targeted genomic editing makes it possible to disrupt or modify almost any 
locus of interest in an ever-expanding array of organisms (Gaj et al., 2013). We now have 
the ability to carry out the majority of genetic manipulations equally well in both mouse 
and zebrafish. There are great benefits of working with both species simultaneously. Mouse 
is an ideal organism for modeling human disease because they more closely resemble 
human in terms of underlying physiology and genomic organization. In addition, extensive 
resources, such as International Knockout Mouse Consortium (IKMC), Knockout Mouse 
Project Repository (KOMP), Allen Brain Atlas, and GenePaint, already exist as a result of 
collaborative efforts to facilitate functional studies in mice. On the other hand, zebrafish is 
an ideal organism for early developmental studies and high throughput screening because 
of their optical transparency, big clutch size and rapid ex vivo development. By comparing 
and contrasting between zebrafish and mouse, we can more readily obtain insightful 
understanding of the universal biological principles.  
Diabetes and pancreatic cancer are two devastating diseases of the pancreas. My 
thesis work is on the basic science aspects of the pancreas; but hopefully, it will provide 
some incremental knowledge to help bridge the gap from benchside to bedside. There are 
several points I would like to emphasize. First, the lineage tracing work demonstrates that 
a reduced level of ptf1a is more conducive to β cells differentiation. This may guide us in 
designing a more efficient protocol for the derivation of β cells in vitro. Second, in the adult 
pancreas, A+Sca-1+ cells have great potentials in both serving as a source for new β cells 
and providing a supportive niche for proper cellular differentiation. Third, the level of 
Dicer is tightly regulated during the initiation of pancreatic cancer. The oncogenic as well 
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as tumor suppressor roles of Dicer seems to be context-dependent and warrants further 
intensive research to evaluate its feasibility as a therapeutic target.  My thesis work is 
definitely not conclusive and a lot more work is needed to carry each project further. 
Nevertheless, I hope it has provided some insight into the pancreatic biology. May we one 
day find the cure for both diabetes and pancreatic cancer.  
6.2 Limitations and Future directions 
There are several limitations in my work.  
In Chapter 2, we utilized the ptf1a:creERT2;ubi:loxp-CFP-loxp-nuclear-mCherry 
double transgenic fish to map the lineage of ptf1a. We did not observe large contributions 
of the early ptf1a-expressing cells to endocrine nor PNCs. However, negative results from 
this lineage tracing experiment could have been explained by numerous factors rather than 
true noncontribution (Kawaguchi et al., 2011). In our case, potential issues include low 
efficiency of labelling; inappropriate timing of 4-OHT administration; and slow kinetics of 
Cre. Moreover, the ptf1a:creERT2 allele is carried by a randomly integrated BAC transgene. 
It may not retain all the regulatory elements of the native ptf1a genomic locus or suffer 
from position effects (Wilson et al., 1990). As a result, it may not reliably follow the 
endogenous expression pattern. In addition, we claimed that the Sanger mutant ptf1asa126 
was a null or hypomorphic allele, however, biochemical quantification of the dosage of 
functional Ptf1a is lacking. We may also take advantage of the other ptf1a hypomorphic 
mutant akreas line (Dong et al., 2008) to generate an assemblage of zebrafish lines 
containing different dosages of ptf1a to address the threshold effect of ptf1a in cell fate 
determination in detail.  
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In Chapter 3, we identified an A+Sca-1+ population that have progenitor cell 
properties. However, we did not have a lineage tracing strategy to map the fates of these 
cells in vivo and hence we are not clear of the endogenous functions of this population. 
Furthermore, we found that this population secretes a number of cytokines that were 
similarly secreted by embryonic pancreatic mesenchymes. But whether these cytokines 
play a role in paracrine signals and what the targets are remain to be addressed. Similarly, 
the upregulation of A+Sca-1+ population during acute pancreatitis was purely an 
observation. We do not have evidence of its functional significance. 
In Chapter 4, we studied the role of Dicer in mature acinar cells using 
Mist1CreERT2/+;Dicerfl/fl transgenic mice. However, we did not know whether the effects of 
Dicer deletion were due to the depletion of miRNAs or through miRNA-independent Dicer 
mechanism. The observation that under conditions of oncogenic Kras activation, there was 
tissue-wide Dicer downregulation is interesting but we did not know the mechanism. At 
the same time, we did not have an accurate assessment of the extent of Dicer 
downregulation in the context of different genotypes or in different ADM and PanIN 
lesions. Also, we only examined the Dicer depletion phenotypes in the Kras activation 
condition by means of tissue histology, but we did not collect information of the overall 
survival status of the corresponding transgenic mice. Detailed miRNA microarray studies 
should also be carried out to monitor the expression profile of each individual miRNA.  
In Chapter 5, we developed a zebrafish model of pancreatic cancer. However, the 
cancer incidence was only about 11% in contrast to the near 100% penetrance of in the 
corresponding mouse models of pancreatic cancer. In addition, the earliest time at which 
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we started to observe histological abnormalities in zebrafish was around 24 weeks. The 
problem of low penetrance and slow time course of our system need to be solved before 
the strategy can be used effectively in downstream applications such as high throughput 
drug screening and functional genomics. Furthermore, the study of the role of mir-216b-
217 in pancreatic cancer initiation is currently not complete.  
Everything considered, tissue specification and fate maintenance is a tightly 
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